

Author index*

A

- Abdelhamed AI, Reis SE, Sane DC, Brosnihan KB, Preli RB, Herrington DM. No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. 2003;145:e15
- Abedin M, McGuire DK. Don't miss this opportunity: diagnosing diabetes. 2003;145:195-7 (Editorial)
- Abouzar L (see Crystal et al). 2003;145:174-8 (Trial design)
- Abt B (see Unverdorben et al). 2003;145:e17
- Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators (see Gheorghiade et al). 2003;145:S51-4
- Adamowicz-Czoch E (see Poloski et al). 2003;145:855-61
- Adams-Campbell LL (see Khurana et al). 2003;145:724-9
- Adams KF Jr, Mathur VS, Gheorghiade M. B-Type natriuretic peptide: from bench to bedside. 2003;145:S34-46
- Adams KF Jr (see Felker et al). 2003;145:S18-25
- Adams KF Jr (see Gheorghiade et al). 2003;145:S1-2, S51-4, S55-7, S67-70
- Adams KF Jr (see O'Connor et al). 2003;145:S47-50, S58-9
- Adams KF Jr (see Zampino et al). 2003;145:S62-6
- Adgey AAJ (see Menown et al). 2003;145:986-92
- Agranat O (see Goldenberg et al). 2003;145:862-7
- Ahmed A, Allman RM, Kiefe CJ, Person SD, Shaneyfelt TM, Sims RV, Howard G, DeLong JF. Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care. 2003;145:1086-93
- Ahn YS (see Bernal-Mizrahi et al). 2003;145:962-70 (Progress cardi-ol.)
- Airola F (see Briguori et al). 2003;145:700-7
- Akyurek O, Berkalp B, Sayin T, Kumbasar D, Kervanciolu C, Oral D. Altered coronary flow properties in diffuse coronary artery ectasia. 2003;145:66-72
- Alegria E (see Mitrovic et al). 2003;145:e14
- Alexander JH (see Serebruany et al). 2003;145:636-42
- Alexander K (see Frazier and Alexander). 2003;145:206-8 (Editorial)
- Alexander KP (see Pasquali et al). 2003;145:445-51
- Alexopoulos D, Toulgaridis T, Davlouros P, Christodoulou J, Sitafidis G, Hahalis G, Vagenakis AG. Prognostic significance of coronary artery calcium in asymptomatic subjects with usual cardiovascular risk. 2003;145:542-8
- Alfonso F, Garcia P, Pimentel G, Hernandez R, Sabaté M, Escaned J, Bañuelos C, Fernández C, Macaya C. Predictors and implications of residual plaque burden after coronary stenting: an intravascular ultrasound study. 2003;145:254-61
- Alford AB (see Gurbel et al). 2003;145:239-47
- Allman RM (see Ahmed et al). 2003;145:1086-93
- Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. 2003;145:248-53
- Alonso R (see Mozas et al). 2003;145:999-1005
- Alter DA (see Austin et al). 2003;145:27-35
- Ambrosioni E (see Borghi et al). 2003;145:80-7
- Amin J (see Padmanabhan et al). 2003;145:132-8
- Anderson JL (see Jackson et al). 2003;145:875-81
- Andrieu R (see Bauriedel et al). 2003;145:343-8
- Annex BH (see Ketyeyan et al). 2003;145:912-18
- Annex BH (see Rajagopalan et al). 2003;145:1114-18
- Ansari MN (see Massie and Ansari). 2003;145:209-13 (Editorial)
- Antman EM (see Bahit et al). 2003;145:109-17
- Apstein CS (see Ekery et al). 2003;145:896-902
- Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, Leach D, Lopez LM, Hill JA. Comparison of

dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. 2003;145:324-9

- Arens HA (see Mitrovic et al). 2003;145:e14
- Argano C (see Licata et al). 2003;145:459-66
- Armstrong PW (see Al-Khatib et al). 2003;145:515-21
- Armstrong PW (see Batchelor et al). 2003;145:349-55
- Armstrong PW (see Welsh et al). 2003;145:1-8 (Progress cardi-ol.)
- Arnett DK (see Palmieri et al). 2003;145:1071-7
- Ashfaq S (see Ghazzal et al). 2003;145:1006-12
- Attenhofer Jost CH, Pellikka PA. Atropine for inconclusive exercise tests: a beautiful solution or just cosmetics? 2003;145:938-40 (Editorial)
- Auer J, Berent R, Weber T, Eber B. Cytomegalovirus seropositivity, infectious burden, and coronary artery disease. 2003;145:e9 (Letter)
- Austin PC, Tu JV, Alter DA. Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? 2003;145:27-35
- Ayers GM (see Frykman et al). 2003;145:670-5

B

- Baer FM (see Schneider et al). 2003;145:e4
- Baggi JM Jr (see Maia et al). 2003;145:e27
- Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald E. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. 2003;145:109-17
- Bair TL (see Jackson et al). 2003;145:875-81
- Bairos L (see Pescatello et al). 2003;145:364-70
- Banai S (see Almagor et al). 2003;145:248-53
- Bang A (see Engdahl et al). 2003;145:826-33
- Bañuelos C (see Alfonso et al). 2003;145:254-61
- Baram S, McCrindle BW, Han RK, Benson LN, Freedom RM, Nykanen DG. Outcomes of uncomplicated aortic valve stenosis presenting in infants. 2003;145:1063-70
- Barbagelata A (see Gheorghiade et al). 2003;145:S51-4
- Barnard MR (see Furman et al). 2003;145:e6
- Bashore TM (see Lapeyre et al). 2003;145:1051-7
- Batchelor WB, Mark DB, Knight JD, Granger CB, Armstrong PW, Califf RM, Peterson ED. Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada. 2003;145:349-55
- Battler A (see Hasdai et al). 2003;145:73-9
- Bauriedel G, Skowasch D, Schneider M, Andrieu R, Jabs A, Lüderitz B. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. 2003;145:343-8
- Beck C (see Simpson et al). 2003;145:438-44
- Behrendt D (see Resnic et al). 2003;145:42-6
- Bell CR (see Gurbel et al). 2003;145:239-47
- Bella JN (see Castello et al). 2003;145:535-41
- Bella JN (see Palmieri et al). 2003;145:1071-7
- Ben-Ami M (see Blum et al). 2003;145:e7
- Bengolea V (see Ruiz et al). 2003;145:834-40
- Benson LN (see Baram et al). 2003;145:1063-70
- Bentley J (see Cotter et al). 2003;145:622-7
- Benun J, Fisher SD, Orav EJ, Schwartz ML, Exil V, Messere C, Lipshultz SE. Cardiac management by pediatricians versus pediatric cardiologists in an inpatient academic center. 2003;145:424-9
- Beohar N (see Ricciardi et al). 2003;145:522-8
- Berent R (see Auer et al). 2003;145:e9 (Letter)
- Berczin R (see Reynolds et al). 2003;145:334-42
- Berezin R (see Taira et al). 2003;145:452-8

*January, pp. 1-186; February, part 1, pp. 187-376; part 2, pp. 51-570; March, pp. 377-562; April, pp. 563-748; May pp. 749-932; June, pp. 933-1148.

- Berger P (see Steinhilber and Berger). 2003;145:971-8 (Progress cardi.)
- Berkalp B (see Akyurek et al). 2003;145:66-72
- Berlin JA (see Kizer et al). 2003;145:683-92
- Bernal-Mizrahi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. 2003;145:962-70 (Progress cardi.)
- Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. 2003;145:1036-45
- Berry SM (see Berry et al). 2003;145:1036-45
- Berthold HK (see Unverdorben et al). 2003;145:e17
- Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-Reactive protein in acute myocardial infarction: association with heart failure. 2003;145:1094-101
- Best L (see Palmieri et al). 2003;145:467-74
- Best PJM, Holmes DR Jr. Chronic kidney disease as a cardiovascular risk factor. 2003;145:383-6 (Editorial)
- Bhatt DL (see Gerschutz and Bhatt). 2003;145:595-601 (Progress cardi.)
- Binbrek A (see Serebruany et al). 2003;145:636-42
- Birkmeyer NJO (see Nowicki et al). 2003;145:1058-62
- Blatt A (see Cotter et al). 2003;145:622-7
- Blebea J (see Rajagopalan et al). 2003;145:1114-18
- Bloemenkamp DGM, Mali WPTHM, Visseren FLJ, van der Graaf Y. Meta-analysis of sero-epidemiologic studies of the relation between *Chlamydia pneumoniae* and atherosclerosis: does study design influence results? 2003;145:409-17 (Progress cardi.)
- Blum A, Lang N, Peleg A, Vigder F, Israeli P, Gumanovsky M, Lupovitz S, Elgazi A, Ben-Ami M. Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia. 2003;145:e7
- Bode F (see Bonnemeyer et al). 2003;145:484-92
- Boehm BO (see Taubert et al). 2003;145:285-91
- Bonemeyer H, Wiegand UKH, Giannitsis E, Schlenburg S, Hartmann F, Kurowski V, Bode F, Tölg R, Katus HA, Richardt G. Temporal repolarization inhomogeneity and reperfusion arrhythmias in patients undergoing successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: impact of admission troponin T. 2003;145:484-92
- Bonow RO (see Ricciardi et al). 2003;145:522-8
- Bonz AW, Lengenfelder B, Jacobs M, Strotmann J, Held S, Ertl G, Voelker W. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. 2003;145:693-9
- Booth JV, Phillips-Bute B, McCants CB, Podgoreanu MV, Smith PK, Mathew JP, Newman MF. Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery. 2003;145:1108-13
- Boothroyd DB (see Melsop et al). 2003;145:36-41
- Borges-Neto S (see Bourque et al). 2003;145:758-67 (Curriculum cardi.)
- Borghi C, Ambrosioni E, SMILE-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. 2003;145:80-7
- Bosimini E (see Mezzani et al). 2003;145:1102-7
- Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. 2003;145:233-8
- Bourgault C (see Brassard et al). 2003;145:e25
- Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, O'Connor CM. Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 2003;145:758-67 (Curriculum cardi.)
- Boutchee KL (see Ting et al). 2003;145:278-84
- Bradley WA (see Piper et al). 2003;145:1022-9
- Brandt JM (see Maia et al). 2003;145:e27
- Brassard P, Bourgault C, Brophy J, Kezouh A, Rainville B, Xhignesse M, Suissa S. Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension. 2003;145:e25
- Braunwald E (see Bahit et al). 2003;145:109-17
- Braunwald E (see Cotter et al). 2003;145:622-7
- Brawner CA (see Keteeyan et al). 2003;145:912-18
- Bricker JT (see Riveness et al). 2003;145:716-23
- Briguori C, Sarais C, Pagnotta P, Airolidi F, Liistro F, Sgura F, Spanos V, Carlino M, Montorfano M, Di Mario C, Colombo A. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty. 2003;145:700-7
- Brindis RG, Sennett C. Physician adherence to clinical practice guidelines: does it really matter? 2003;145:13-15 (Editorial)
- Broderick TM (see Furman et al). 2003;145:e6
- Brodie BR, Stuckey TD, Muncy DB, Hansen CJ, Wall TC, Pulsipher M, Gupta N. Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. 2003;145:708-15
- Brophy J (see Brassard et al). 2003;145:e25
- Brosnihan KB (see Abdelhamed et al). 2003;145:e15
- Browett PJ (see French et al). 2003;145:118-24
- Bruckman D (see Kim et al). 2003;145:665-9
- Buchbinder M (see Mauri et al). 2003;145:847-54
- Buchthal S (see Marroquin et al). 2003;145:628-35
- Bui S (see Mazeika et al). 2003;145:1013-21
- Bunch TJ (see Jackson et al). 2003;145:875-81

C

- Cadena CN (see Oropeza and Cadena). 2003;145:317-23
- Califf RM (see Al-Khatib et al). 2003;145:515-21
- Califf RM (see Batchelor et al). 2003;145:349-55
- Califf RM (see Reddan et al). 2003;145:586-94 (Curriculum cardi.)
- Callahan KP (see Serebruany et al). 2003;145:636-42
- Calvar C (see Ruiz et al). 2003;145:834-40
- Campana C (see Gavazzi et al). 2003;145:310-16
- Campeau L (see Knatterud et al). 2003;145:262-9
- Canadian Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) Investigators (see Rouleau et al). 2003;145:926-32
- Cannon CP (see Bahit et al). 2003;145:109-17
- Cannon CP (see Cotter et al). 2003;145:622-7
- Cardinale A (see Licata et al). 2003;145:459-66
- Carlino M (see Briguori et al). 2003;145:700-7
- Carroll S (see Connolly et al). 2003;145:226-32
- Caspi A (see Cotter et al). 2003;145:622-7
- Casscells W, Hassan K, Vaseghi MF, Siadat MS, Naghavi M, Kirkeeide RL, Hassan MR, Madjid M. Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses. 2003;145:813-20
- Castello R, Bella JN, Rovner A, Swan J, Smith J, Shaw L. Efficacy and time-efficiency of a "sonographer-driven" contrast echocardiography protocol in a high-volume echocardiography laboratory. 2003;145:535-41
- Castillo S (see Mozas et al). 2003;145:999-1005
- Celentano A (see Palmieri et al). 2003;145:467-74
- Cenarro A (see Mozas et al). 2003;145:999-1005
- Channer KS (see Pugh et al). 2003;145:e11 (Letter)
- Charlesworth A (see Cotter et al). 2003;145:622-7
- Chazin-Caldie M (see Kandzari et al). 2003;145:868-74
- Chen Y-T (see Chou et al). 2003;145:169-73
- Chirife R (see Ruiz et al). 2003;145:834-40
- Cho S (see Partington et al). 2003;145:139-46
- Chou H-T, Chen Y-T, Shi Y-R, Tsai F-J. Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and mitral valve prolapse syndrome. 2003;145:169-73
- Chow C-M (see Fox et al). 2003;145:730-6
- Christian TF (see Lapeyre et al). 2003;145:357-63

- Christodoulou J (see Alexopoulos et al). 2003;145:542-8
Chun S (see Partington et al). 2003;145:139-46
Ciewierz D (see Gruchaa et al). 2003;145:125-31
Civeira F (see Mozas et al). 2003;145:999-1005
Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. 2003;145:387-96 (Curriculum cardiol.)
Cleaton TS (see Aranda et al). 2003;145:324-9
Clough RA (see Nowicki et al). 2003;145:1058-62
Coats AJS (see Russell et al). 2003;145:179-86 (Trial design)
Coen MM (see Marso et al). 2003;145:270-7
Coffman CJ (see Indridason et al). 2003;145:300-9
Cohen DJ (see Reynolds et al). 2003;145:334-42
Cohen DJ (see Taira et al). 2003;145:452-8
Col JJ (see Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)
Colan SD (see Rivenes et al). 2003;145:716-23
Collins V (see Pescatello et al). 2003;145:364-70
Colombo A (see Briguori et al). 2003;145:700-7
Conard M (see Haddock et al). 2003;145:652-7
Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O'Brien B, Carroll S, Crystal E, Thorpe KE, Gent M. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the β -Blocker Length Of Stay (BLOS) study. 2003;145:226-32
Connolly SJ. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. 2003;145:418-23 (Progress cardiol.)
Connolly SJ (see Crystal et al). 2003;145:174-8 (Trial design)
Connolly SJ (see Newman et al). 2003;145:430-7
Cooke G (see French et al). 2003;145:118-24
Coombs LP (see Pasquali et al). 2003;145:445-51
Cordeiro JA (see Maia et al). 2003;145:e27
Cordiano R (see Berton et al). 2003;145:1094-101
Corliss MS (see Piper et al). 2003;145:1022-9
Corrà U (see Mezzani et al). 2003;145:1102-7
Cosgrove R (see Taira et al). 2003;145:452-8
Cosgrove RS (see Reynolds et al). 2003;145:334-42
Cotter C, Cannon CP, McCabe CH, Michowitz Y, Kalusi E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E, OPUS-TIMI 16 Investigators. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. 2003;145:622-7
Cox JL (see Wood et al). 2003;145:806-12 (Progress cardiol.)
Coyle LC (see Kent et al). 2003;145:e8
Cragun KT (see Ting et al). 2003;145:278-84
Crocker CH (see Ting et al). 2003;145:278-84
Crossman DC (see Hauser et al). 2003;145:602-13
Crystal E, Lamy A, Connolly SJ, Kleine P, Hohnloser SH, Semelthago L, Abouzar L, Cybulsky I, Shragge B, Teoh K, Lonn E, Sawchuk C, Oezaslan F. Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. 2003;145:174-8 (Trial design)
Crystal E (see Connolly et al). 2003;145:226-32
CTOPP Investigators (see Newman et al). 2003;145:430-7
Cuffie MS. Impacting the use of the screening electrocardiogram. 2003;145:936-7 (Editorial)
Cummings CC (see Gurbel et al). 2003;145:239-47
Cummings G (see Munagala et al). 2003;145:1046-50
Cusma JT (see Ting et al). 2003;145:278-84
Cutlip DE (see Mauri et al). 2003;145:847-54
Cybulsky I (see Connolly et al). 2003;145:226-32
Cybulsky I (see Crystal et al). 2003;145:174-8 (Trial design)

D

- Dabrowski M (see Mitrovic et al). 2003;145:e14
Dacey LJ (see Nowicki et al). 2003;145:1058-62

- Daemgen G (see Unverdorben et al). 2003;145:e17
Dahlöf B (see Oikarinen et al). 2003;145:919-25
Daley JR (see Lapeyre et al). 2003;145:357-63
Dalsey WC (see Hillis et al). 2003;145:88-94
Danoff TM (see Holmes and Danoff). 2003;145:e22 (Letter reply)
Darpö B (see Frykman et al). 2003;145:670-5
Davidoff R (see Ekery et al). 2003;145:896-902
Davidson CJ (see Ricciardi et al). 2003;145:522-8
Davlouros P (see Alexopoulos et al). 2003;145:542-8
Dawn B (see Stoddard et al). 2003;145:676-82
De Caterina R (see Gianetti and De Caterina). 2003;145:e13 (Letter reply)
de Godoy MF (see Maia et al). 2003;145:e27
de Lemos JA (see Morrow and de Lemos). 2003;145:380-2 (Editorial)
de Marchena E (see Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardiol.)
de Meester A (see Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)
de Simone G (see Palmieri et al). 2003;145:467-74
Decena BF (see Kim et al). 2003;145:665-9
Degenhardt R (see Unverdorben et al). 2003;145:e17
Dei Cas L (see Metra et al). 2003;145:292-9
DeLong E. Hierarchical modeling: its time has come. 2003;145:16-18 (Editorial)
DeLong JF (see Ahmed et al). 2003;145:1086-93
Dens J, Desmet W, Piessens J. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. 2003;145:404-8 (Progress cardiol.)
Dery J-P, Hernandez AF, Kay JD, Petersen JL, Rao SV, Rebeiz AG, Singh KP, Donahue MP. Highlights from the American Heart Association Annual Scientific Sessions 2002: November 17 to 20, 2002. 2003;145:554-62 (Meetings)
Desmet W (see Dens et al). 2003;145:404-8 (Progress cardiol.)
Detrano RC (see Khurana et al). 2003;145:724-9
Devereux RB (see Oikarinen et al). 2003;145:919-25
Devereux RB (see Palmieri et al). 2003;145:467-74, 1071-7
Dhalla KS (see Rouleau et al). 2003;145:926-32
Dhalla NS (see Rouleau et al). 2003;145:926-32
Dhanekula LS (see Botkin et al). 2003;145:233-8
Di Mario C (see Briguori et al). 2003;145:700-7
Di Pasquale P (see Licata et al). 2003;145:459-66
Di Segni E (see Goldenberg et al). 2003;145:862-7
Dickstein K. What did we learn from the OPTIMAAL trial? What can we expect from VALLANT? 2003;145:754-7 (Editorial)
DiPasquale C (see Pescatello et al). 2003;145:364-70
Doba N (see Tomiyama et al). 2003;145:e2
Domanski M (see Knatterud et al). 2003;145:262-9
Donahue MP (see Dery et al). 2003;145:554-62 (Meetings)
Dorian P (see Newman et al). 2003;145:430-7, 841-6
Douglas JS (see Ghazzal et al). 2003;145:1006-12
Drazner MH, Palmer BF. Hypertonic saline: a novel therapy for advanced heart failure? 2003;145:377-9 (Editorial)
Dubaniewicz W (see Gruchaa et al). 2003;145:125-31
Dukl A (see Mitrovic et al). 2003;145:e14
Duke University Cooperative Cardiovascular Studies (DUCCS) Investigators (see Gheorghade et al). 2003;145:855-7
Duscha BD (see Ketyeyan et al). 2003;145:912-18
Dzhanashvili AI (see Malinin et al). 2003;145:397-403 (Curriculum cardiol.)

E

- Eagle KA (see Kim et al). 2003;145:665-9
Easley KA (see Rivenes et al). 2003;145:716-23
Eber B (see Auer et al). 2003;145:e9 (Letter)
Eckman LJ (see Ricciardi et al). 2003;145:522-8
Edmundowicz D (see Marroquin et al). 2003;145:628-35
Egstrup K (see Moller et al). 2003;145:147-53
Egstrup K (see Sondergaard et al). 2003;145:e24

- Eisenberg MJ (see Simpson et al). 2003;145:438-44
 Eisenberg MS (see Rea and Eisenberg). 2003;145:749-50 (Editorial)
 Ekery DL, Davidoff R, Orlandi QG, Apstein CS, Hesselvik JF, Shemin RJ, Shapira OM. Diastolic dysfunction after coronary artery bypass grafting: a frequent finding of clinical significance not influenced by intravenous calcium. 2003;145:896-902
 Elgazi A (see Blum et al). 2003;145:e7
 Elian D (see Goldenberg et al). 2003;145:862-7
 Elkayam U (see Gheorghiade et al). 2003;145:S51-4
 Engdahl J, Bång A, Lindqvist J, Herlitz J. Time trends in long-term mortality after out-of-hospital cardiac arrest, 1980 to 1998, and predictors for death. 2003;145:826-33
 Epstein AM (see Leape et al). 2003;145:19-26
 Erbs S (see Gielen et al). 2003;145:e3
 Ertl G (see Bonz et al). 2003;145:693-9
 Escaned J (see Alfonso et al). 2003;145:254-61
 Eskilsson J (see Tingberg et al). 2003;145:e1
 Esler A (see Havranek et al). 2003;145:993-8
 Estacio RO (see Havranek et al). 2003;145:993-8
 Evans MA (see Lapeyre et al). 2003;145:357-63
 Every NR (see Rumsfeld et al). 2003;145:493-9
 Exil V (see Benun et al). 2003;145:424-9

F

- Fabsitz RR (see Palmieri et al). 2003;145:467-74
 Fang ZY, Marwick TH. Mechanisms of exercise training in patients with heart failure. 2003;145:904-11
 Farias EF (see Perna et al). 2003;145:e19 (Letter reply)
 Farrell KL (see Piper et al). 2003;145:1022-9
 Fassbender S (see Schneider et al). 2003;145:e4
 Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. 2003;145:943-51 (Curriculum cardiolo.)
 Fearon WF, Yeung AC, Lee DP, Yock PG, Heidenreich PA. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions. 2003;145:882-7
 Feinberg MS, Scheinowitz M, Laron Z. Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. 2003;145:549-53
 Felker GM, Adams KF Jr, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. 2003;145:S18-25
 Felker GM, O'Connor CM. A bridge for the 21st century in heart transplantation? 2003;145:198-9 (Editorial)
 Fernández C (see Alfonso et al). 2003;145:254-61
 Fisher SD (see Benun et al). 2003;145:424-9
 Flaherty PJ (see Kent et al). 2003;145:e8
 Flossbach CW (see Kleber et al). 2003;145:614-21
 Fogel MA, Weinberg PM, Haselgrove J. Flow volume asymmetry in the right aortic arch in children with magnetic resonance phase encoded velocity mapping. 2003;145:154-61
 Follone G (see Licata et al). 2003;145:459-66
 Forder P (see Hague et al). 2003;145:643-51
 Forman SA (see Knatterud et al). 2003;145:262-9
 Forrester JS (see Knatterud et al). 2003;145:262-9
 Fox ER, Picard MH, Chow C-M, Levine RA, Schwamm L, Kerr AJ. Interatrial septal mobility predicts larger shunts across patent foramen ovals: an analysis with transmitral Doppler scanning. 2003;145:730-6
 Fox ML (see Furman et al). 2003;145:e6
 Francis GS, Tang WHW. β -Blockers and reverse remodeling: what are the implications? 2003;145:200-2 (Editorial)
 Franklin SS (see Wong et al). 2003;145:888-95
 Franzosi MG (see Vilella et al). 2003;145:475-83
 Frazier C, Alexander K. The finer points of race and hypertension. 2003;145:206-8 (Editorial)
 Freedom RM (see Baram et al). 2003;145:1063-70
 Freimark D (see Goldenberg et al). 2003;145:862-7

- Frelinger AL III (see Furman et al). 2003;145:e6
 French JK, Ramanathan K, Stewart JT, Gao W, Thérioux P, White HD. A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. 2003;145:508-14
 French JK, Van de Water NS, Sutton TM, Lund M, Gao WZ, McDowell J, Liu-Stratton Y, Pohorence J, Szymanski D, Goldschmidt-Clermont P, White HD, Browett PJ, Cooke G. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. 2003;145:118-24
 French JK (see Wong et al). 2003;145:95-102
 Frey A (see O'Connor et al). 2003;145:S58-9
 Fries R (see Unverdorben et al). 2003;145:e17
 Froelicher V (see Partington et al). 2003;145:139-46
 Frykman V, Ayers GM, Darpo B, Rosenqvist M. What characterizes episodes of atrial fibrillation requiring cardioversion? Experience from patients with an implantable atrial cardioverter. 2003;145:670-5
 Fujita M, Mizuno K, Ho M, Tsukahara R, Miyamoto A, Miki O, Ishii K, Miwa K. Sarpogrelate treatment reduces restenosis after coronary stenting. 2003;145:e16
 Fung W-H (see Yu et al). 2003;145:e23
 Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL III, Michelson AD. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. 2003;145:e6
 Füssli R (see Schneider et al). 2003;145:e4

G

- Gsior M (see Poloski et al). 2003;145:855-61
 Gallagher JJ (see Littmann et al). 2003;145:768-78 (Curriculum cardiolo.)
 Gao W (see French et al). 2003;145:508-14
 Gao W (see Wong et al). 2003;145:95-102
 Gao WZ (see French et al). 2003;145:118-24
 García-Alvarez I (see Mozas et al). 2003;145:999-1005
 García P (see Alfonso et al). 2003;145:254-61
 Gardin JM (see Munagala et al). 2003;145:1046-50
 Garratt KN (see Ting et al). 2003;145:278-84
 Gatsonis C (see Leape et al). 2003;145:19-26
 Gattis WA (see Gheorghiade et al). 2003;145:S1-2, S51-4, S55-7, S60-1, S67-70
 Gattis WA (see Jain et al). 2003;145:83-17
 Gattis WA (see O'Connor et al). 2003;145:S47-50, S58-9
 Gattis WA (see Zampino et al). 2003;145:S62-6
 Gattone M. Cytomegalovirus seropositivity, infectious burden, and coronary artery disease. 2003;145:e10 (Letter reply)
 Gavazzi A, Ghio S, Scelsi L, Campana C, Klersy C, Serio A, Rainieri C, Tavazzi L. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. 2003;145:310-16
 Geller NL (see Knatterud et al). 2003;145:262-9
 Gelpi RJ (see Ruiz et al). 2003;145:834-40
 Gent M (see Connolly et al). 2003;145:226-32
 Gent M (see Newman et al). 2003;145:430-7
 Gerschutz GP, Bhatt DL. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? 2003;145:595-601 (Progress cardiolo.)
 Gersh BJ (see Kullo and Gersh). 2003;145:941-2 (Editorial)
 Gevorkian N (see Gruberg et al). 2003;145:529-34
 Ghali JK. Heart failure with preserved systolic function after myocardial infarction: a growing burden? 2003;145:575-8 (Editorial)
 Ghazal Z, Ashfaq S, Morris DC, Douglas JS, Marshall JJ, King SB III, Weintraub WS. Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIIb/IIIa antagonist era. 2003;145:1006-12
 Ghaziz MM (see Russell et al). 2003;145:179-86 (Trial design)

- Gheorghiade M, Adams KF Jr, Gattis WA, Teerlink JR, Orlandi C, O'Connor CM. Surrogate end points in heart failure trials. 2003; 145:S67-70
- Gheorghiade M, Gattis WA, Adams KF Jr, Jaffe AS, O'Connor CM, Duke University Cooperative Cardiovascular Studies (DUCCS) Investigators. Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRE-SERVD-HF). 2003;145:S55-7
- Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O'Connor CM. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. 2003;145:S51-4
- Gheorghiade M, Gattis WA, Lukas MA, O'Connor CM, IMPACT-HF Investigators. Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. 2003;145:S60-1
- Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr. The management of decompensated heart failure resulting in hospitalization: proceedings from an expert meeting to review current concepts and to define future directions—Introduction. 2003; 145:S1-2
- Gheorghiade M (see Adams et al). 2003;145:S34-46
- Gheorghiade M (see Felker et al). 2003;145:S18-25
- Gheorghiade M (see Jain et al). 2003;145:S3-17
- Gheorghiade M (see O'Connor et al). 2003;145:S47-50, S58-9
- Gheorghiade M (see Zampino et al). 2003;145:S62-6
- Ghio S (see Gavazzi et al). 2003;145:310-16
- Gianetti J, De Caterina R. Prostaglandin E₂ temporarily decreases adhesion molecules. 2003;145:e13 (Letter reply)
- Giannitsis E (see Bonnemeier et al). 2003;145:484-92
- Giannuzzi P (see Mezzani et al). 2003;145:1102-7
- Gibbons RJ (see Lapeyre et al). 2003;145:357-63, 1051-7
- Gibson CM (see Bahit et al). 2003;145:109-17
- Gielen S, Erbs S, Linke A, Möbius-Winkler S, Schuler G, Hambrecht R. Home-based versus hospital-based exercise programs in patients with coronary artery disease: effects on coronary vasomotion. 2003;145:e3
- Gierlotka M (see Poloski et al). 2003;145:855-61
- Giordano A (see Mezzani et al). 2003;145:1102-7
- Giorgi LV (see Marso et al). 2003;145:270-7
- GLSI-2 Investigators (see Vilella et al). 2003;145:475-83
- Giubbini R (see Metra et al). 2003;145:292-9
- Gobel FL (see Knatterud et al). 2003;145:262-9
- Gök R (see Taubert et al). 2003;145:285-91
- Gold MR (see Newman et al). 2003;145:841-6
- Goldberg RJ (see Spencer et al). 2003;145:500-7
- Goldberg S (see Kandzari et al). 2003;145:868-74
- Goldenberg I, Matetzky S, Halkin A, Roth A, Di Segni E, Freimark D, Elian D, Agranat O, Zahav YH, Guetta V, Hod H. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. 2003; 145:862-7
- Goldman C (see Rajagopalan et al). 2003;145:1114-18
- Goldschmidt-Clermont P (see French et al). 2003;145:118-24
- Gore JM (see Spencer et al). 2003;145:500-7
- Goss JR (see Maynard et al). 2003;145:658-64
- Gracey HM (see Menown et al). 2003;145:986-92
- Granger CB (see Al-Khatib et al). 2003;145:515-21
- Granger CB (see Batchelor et al). 2003;145:349-55
- Granger CB (see Hasdai et al). 2003;145:73-9
- Granger CB (see Hauser et al). 2003;145:602-13
- Granger CB (see Serebruany et al). 2003;145:636-42
- Green HJ (see Keteyian et al). 2003;145:912-18
- Grossman PM (see Mehta et al). 2003;145:1078-85
- Gruber L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Sattler LF, Suddath WO, Pinnow EE, Gevorkian N, Lindsay J Jr. Impact of renal function on morbidity and mortality after percutaneous

- aortocoronary saphenous vein graft intervention. 2003;145:529-34
- Gruchaa M, Ciewierz D, Wasag B, Targoski R, Dubaniewicz W, Nowak A, Sobiczewski W, Ochman K, Romanowski P, Limon J, Rynkiewicz A. Association of the *Scal* atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. 2003;145:125-31
- Grunwald GK (see Rumsfeld et al). 2003;145:493-9
- Gubernikoff G (see Ricciardi et al). 2003;145:522-8
- Guduguntla V (see Munagala et al). 2003;145:1046-50
- Guetta V (see Goldenberg et al). 2003;145:862-7
- Gumanovsky M (see Blum et al). 2003;145:e7
- Guo Y-F, Stein PK. Circadian rhythm in the cardiovascular system: chronocardiology. 2003;145:779-86 (Curriculum cardiol.)
- Gupta N (see Brodie et al). 2003;145:708-15
- Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. 2003;145:239-47
- Gurbel PA (see Serebruany et al). 2003;145:636-42
- Gyntelberg F (see Jeppesen et al). 2003;145:103-8

H

- Haddock CK, Poston WSC, Taylor JE, Conard M, Spertus J. Smoking and health outcomes after percutaneous coronary intervention. 2003;145:652-7
- Hafner G (see Ries et al). 2003;145:737-41
- Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. 2003;145:643-51
- Hahalis G (see Alexopoulos et al). 2003;145:542-8
- Haines JL (see Hauser et al). 2003;145:602-13
- Halkin A (see Goldenberg et al). 2003;145:862-7
- Halliburton SS (see Klingensmith et al). 2003;145:795-805 (Progress cardiol.)
- Hambrecht R (see Gielen et al). 2003;145:e3
- Han RK (see Baram et al). 2003;145:1063-70
- Hannan EL, Wu C. Assessing quality and outcomes for percutaneous coronary intervention: choosing statistical models, outcomes, time periods, and patient populations. 2003;145:571-4 (Editorial)
- Hansen CJ (see Brodie et al). 2003;145:708-15
- Hansen MS (see Rouleau et al). 2003;145:926-32
- Harrington RA (see Hasdai et al). 2003;145:73-9
- Hartmann F (see Bonnemeier et al). 2003;145:484-92
- Hasdai D. Endothelium-independent coronary microvascular function: all vessels are not created equally. 2003;145:567-8 (Editorial)
- Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman EM, Granger CB, Van de Werf F, Simoons ML, O'Connor CM, Holmes DR Jr. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 2003;145:73-9
- Haselgrove J (see Fogel et al). 2003;145:154-61
- Hassan K (see Casscells et al). 2003;145:813-20
- Hassan MR (see Casscells et al). 2003;145:813-20
- Hauser ER, Mooser V, Crossman DC, Haines JL, Jones CH, Winkelmann BR, Schmidt S, Scott WK, Roses AD, Pericak-Vance MA, Granger CB, Kraus WE. Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study. 2003;145:602-13
- Havranek EP, Esler A, Estacio RO, Mehler PS, Schrier RW. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. 2003;145:993-8
- Hearne MJ (see Piper et al). 2003;145:1022-9

- Heidenreich PA (see Fearon et al). 2003;145:882-7
 Hein HO (see Jeppesen et al). 2003;145:103-8
 Held S (see Bonz et al). 2003;145:693-9
 Hellermann JP, Jacobsen GS, Lopez-Jimenez F, Weston SA, Roger VL. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. 2003;145:742-8
 Helqvist S (see Jorgensen et al). 2003;145:e5
 Hennen B (see Unverdorben et al). 2003;145:e17
 Herd JA (see Knatterud et al). 2003;145:262-9
 Herlitz J (see Engdahl et al). 2003;145:826-33
 Hermes R (see Ruiz et al). 2003;145:834-40
 Hernandez AF (see Dery et al). 2003;145:554-62 (Meetings)
 Hernández RM (see Alfonso et al). 2003;145:254-61
 Herrington DM (see Abdelhamed et al). 2003;145:e15
 Hesselvik JF (see Ekery et al). 2003;145:896-902
 Hettelman BD (see Piper et al). 2003;145:1022-9
 Hickey A (see Knatterud et al). 2003;145:262-9
 Hikita H (see Nishioka et al). 2003;145:162-8
 Hill JA (see Aranda et al). 2003;145:324-9
 Hillis GS, Taggart P, Hillis L, Zhao N, Dalseg WC, Mangione A. Biochemical and clinical predictors of long-term outcome in patients with nonspecific chest pain and nondiagnostic electrocardiograms. 2003;145:88-94
 Hillis L (see Hillis et al). 2003;145:88-94
 Hintereder G (see Ries et al). 2003;145:737-41
 Hirsch AT (see Rajagopalan et al). 2003;145:1114-18
 Hlatky MA (see Melsop et al). 2003;145:36-41
 Ho KKL (see Mauri et al). 2003;145:847-54
 Ho KKL (see Reynolds et al). 2003;145:334-42
 Ho M (see Fujita et al). 2003;145:e16
 Hod H (see Goldenberg et al). 2003;145:862-7
 Hohnloser SH (see Crystal et al). 2003;145:174-8 (Trial design)
 Hoit BD (see Faulx et al). 2003;145:943-51 (Curriculum cardi.)
 Holmes DR Jr, Danoff TM. Tranilast for restenosis: efficacious or not? 2003;145:e22 (Letter reply)
 Holmes DR Jr (see Best and Holmes). 2003;145:383-6 (Editorial)
 Holmes DR Jr (see Hasdai et al). 2003;145:73-9
 Holmes DR (see Ting et al). 2003;145:278-84
 Holubkov R (see Marroquin et al). 2003;145:628-35
 Hong M-K (see Song et al). 2003;145:371-6
 Hoogwerf BJ (see Knatterud et al). 2003;145:262-9
 Hopkins PN (see Palmieri et al). 2003;145:1071-7
 Höpp HW (see Schneider et al). 2003;145:e4
 Horne BD (see Jackson et al). 2003;145:875-81
 Horstman LL (see Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardi.)
 Houlihan RJ (see Ting et al). 2003;145:278-84
 Howard BV (see Khurana et al). 2003;145:724-9
 Howard BV (see Palmieri et al). 2003;145:467-74
 Howard G (see Ahmed et al). 2003;145:1086-93
 Howard WL (see Furman et al). 2003;145:e6
 Hsia J (see Khurana et al). 2003;145:724-9
 Huber KC (see Marso et al). 2003;145:270-7
 Hunninghake DB (see Knatterud et al). 2003;145:262-9
 Hunt D (see Hague et al). 2003;145:643-51
 Hyder M (see Spencer et al). 2003;145:500-7

I

- Ibrahim H (see Unverdorben et al). 2003;145:e17
 Ikeda U (see Matsui et al). 2003;145:330-3
 IMPACT-HF Investigators (see Gheorghide et al). 2003;145:S60-1
 Indridason OS, Coffman CJ, Oddone EZ. Is specialty care associated with improved survival of patients with congestive heart failure? 2003;145:300-9
 Intermountain Heart Collaborative Study (IHCS) Group (see Jackson et al). 2003;145:875-81
 Irvine J (see Newman et al). 2003;145:430-7
 Ishii K (see Fujita et al). 2003;145:e16

- Iskandrian AE (see Patel and Iskandrian). 2003;145:952-61 (Curriculum cardi.)
 Isojima K (see Nishioka et al). 2003;145:162-8
 Israeli P (see Blum et al). 2003;145:e7

J

- Jabbour S (see Spencer et al). 2003;145:500-7
 Jabs A (see Bauriedel et al). 2003;145:343-8
 Jackson JD, Muhlestein JB, Bunch TJ, Bair TL, Horne BD, Madsen TE, Lappé JM, Anderson JL, Intermountain Heart Collaborative Study (IHCS) Group. β -Blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization. 2003;145:875-81
 Jacobs M (see Bonz et al). 2003;145:693-9
 Jacobs MJ (see Wong et al). 2003;145:888-95
 Jacobsen SJ (see Hellermann et al). 2003;145:742-8
 Jaffe AS (see Gheorghide et al). 2003;145:555-7
 Jain P, Massie BM, Gattis WA, Klein L, Gheorghide M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. 2003;145:S3-17
 Jani K (see Mehta et al). 2003;145:821-5
 Jantus E (see Perna et al). 2003;145:e19 (Letter reply)
 Jenkins KJ (see Rivenes et al). 2003;145:716-23
 Jensen GVH (see Jorgensen et al). 2003;145:e5
 Jeong Y-H (see Song et al). 2003;145:371-6
 Jeppesen J, Hein HO, Suadcani P, Gyneltberg F. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. 2003;145:103-8
 Jern S (see Oikarinen et al). 2003;145:919-25
 Jimenez JJ (see Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardi.)
 Joaquim MR (see Maia et al). 2003;145:e27
 Johnson L (see Newman et al). 2003;145:841-6
 Johnson RG (see Reynolds et al). 2003;145:334-42
 Johnson WL (see Marso et al). 2003;145:270-7
 Johnstone DE (see Wood et al). 2003;145:806-12 (Progress cardi.)
 Jones CH (see Hauser et al). 2003;145:602-13
 Jorgensen B, Thaulow E. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study. 2003;145:1030-5
 Jorgensen E, Kelbæk H, Helqvist S, Jensen GVH, Saunamäki K, Kastrup J, Madsen JK, Klovgaard L, Thuesen L, Villadsen A, van Weert AWM, Reiber JHC. Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DAN-STENT)—a randomized trial comparing a first-generation stent with a second-generation stent. 2003;145:e5
 Jy W (see Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardi.)

K

- Kaluski E (see Cotter et al). 2003;145:622-7
 Kampmann C (see Ries et al). 2003;145:737-41
 Kandzari DE, Goldberg S, Schwartz RS, Chazin-Caldie M, Sketch MH Jr, SCORES SVG Registry Investigators. Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry. 2003;145:868-74
 Kandzari DE, Tchong JE. Double negatives. 2003;145:9-12 (Editorial)
 Kang D-H (see Song et al). 2003;145:371-6
 Kaplan S (see Rivenes et al). 2003;145:716-23
 Kasravi B (see Munagala et al). 2003;145:1046-50
 Kastrup J (see Jorgensen et al). 2003;145:e5
 Katsushika S (see Nishioka et al). 2003;145:162-8
 Katus HA (see Bonnemeier et al). 2003;145:484-92

- Kay JD (see Dery et al). 2003;145:554-62 (Meetings)
- Kelbak H (see Jorgensen et al). 2003;145:e5
- Kelder JC (see ten Berg et al). 2003;145:58-65
- Kellett MA Jr (see Piper et al). 2003;145:1022-9
- Kent KM (see Gruberg et al). 2003;145:529-34
- Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum C-reactive protein. 2003;145:e8
- Kereiakes DJ (see Furman et al). 2003;145:e6
- Keren A (see Almagor et al). 2003;145:248-53
- Kerns WP II (see Littmann et al). 2003;145:768-78 (Curriculum cardiol.)
- Kerr AJ (see Fox et al). 2003;145:730-6
- Kerr C (see Newman et al). 2003;145:430-7
- Kervanciolu C (see Akyurek et al). 2003;145:66-72
- Keteyian SJ, Duschka BD, Brawner CA, Green HJ, Marks CRC, Schachar FH, Annex BH, Kraus WE. Differential effects of exercise training in men and women with chronic heart failure. 2003;145:912-18
- Kezouh A (see Brassard et al). 2003;145:e25
- Khan IA. Atrial stunning: determinants and cellular mechanisms. 2003;145:787-94 (Progress cardiol.)
- Khan IA (see Mehta et al). 2003;145:821-5
- Khan MN (see Rivenes et al). 2003;145:716-23
- Al-Khatib SM, Stebbins AL, Calif RM, Lee KL, Granger CB, White HD, Armstrong PW, Topol EJ, Ohman EM. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 2003;145:515-21
- Khurana C, Rosenbaum CG, Howard BV, Adams-Campbell LL, Detrano RC, Klouj A, Hsia J. Coronary artery calcification in black women and white women. 2003;145:724-9
- Kiefe CI (see Ahmed et al). 2003;145:1086-93
- Kilaru R (see Hasdai et al). 2003;145:73-9
- Kim J-J (see Song et al). 2003;145:371-6
- Kim MH, Decena BF, Bruckman D, Eagle KA. Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. 2003;145:665-9
- Kimmel SE (see Kizer et al). 2003;145:683-92
- King SB III (see Ghazzal et al). 2003;145:1006-12
- Kiowski W (see Mitrovic et al). 2003;145:e14
- Kirkeide RL (see Casscells et al). 2003;145:813-20
- Kirshenbaum JM (see Resnic et al). 2003;145:42-6
- Kitzman DW (see Palmieri et al). 2003;145:1071-7
- Kizer JR, Berlin JA, Laskey WK, Schwartz JS, Sauer WH, Krone RJ, Kimmel SE. Limitations of current risk-adjustment models in the era of coronary stenting. 2003;145:683-92
- Kjelsberg MA (see Ting et al). 2003;145:278-84
- Kleber F-X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flossbach CW, THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. 2003;145:614-21
- Klein B (see Taubert et al). 2003;145:285-91
- Klein L (see Jain et al). 2003;145:53-17
- Kleine P (see Crystal et al). 2003;145:174-8 (Trial design)
- Klersy C (see Gavazzi et al). 2003;145:310-16
- Klingensmith JD, Schoenberger P, Tajadine A, Halliburton SS, Tuzcu EM, Nissen SE, Vince DG. Automated three-dimensional assessment of coronary artery anatomy with intravascular ultrasound scanning. 2003;145:795-805 (Progress cardiol.)
- Klouj A (see Khurana et al). 2003;145:724-9
- Klovgaard L (see Jorgensen et al). 2003;145:e5
- Knatterud GL, White C, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Terrin ML, Rosenberg Y. Post CABG Investigators. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. 2003;145:262-9
- Knight JD (see Batchelor et al). 2003;145:349-55
- Kober L (see Moller et al). 2003;145:147-53
- Kochler H (see Unverdorben et al). 2003;145:e17
- Kondys M (see Poloski et al). 2003;145:855-61
- Kong DF (see Liao and Kong). 2003;145:187-9 (Editorial)
- Kong S-L (see Yu et al). 2003;145:e23
- Konstam MA (see Felker et al). 2003;145:S18-25
- Konz KH (see Schneider et al). 2003;145:e4
- Koppenhagen K (see Kleber et al). 2003;145:614-21
- Krakover R (see Cotter et al). 2003;145:622-7
- Kraus WE (see Hauser et al). 2003;145:602-13
- Kraus WE (see Keteyian et al). 2003;145:912-18
- Krone RJ (see Kizer et al). 2003;145:683-92
- Krueger L (see Pescatello et al). 2003;145:364-70
- Krueger LA (see Firman et al). 2003;145:e6
- Kullo IJ, Gersh BJ. Markers of inflammation and thrombosis: clues to plaque instability? 2003;145:941-2 (Editorial)
- Kumbasar D (see Akyurek et al). 2003;145:66-72
- Kuntz RE (see Mauri et al). 2003;145:847-54
- Kurita A (see Nishioka et al). 2003;145:162-8
- Kurowski V (see Bonnemeyer et al). 2003;145:484-92

L

- Lager RA (see Reynolds et al). 2003;145:334-42
- Lahey SJ (see Nowicki et al). 2003;145:1058-62
- Lai WW (see Rivenes et al). 2003;145:716-23
- Lamy A (see Connolly et al). 2003;145:226-32
- Lamy A (see Crystal et al). 2003;145:174-8 (Trial design)
- Lang N (see Blum et al). 2003;145:e7
- Lapeyre AC III, Evans MA, Christian TF, Daley JR, Gibbons RJ. Comparison of the predischARGE exercise thallium-201 perfusion defect after myocardial infarction with myocardium at risk measured during acute infarction with technetium-99m sestamibi imaging. 2003;145:357-63
- Lapeyre AC III, St Gibson W, Bashore TM, Gibbons RJ. Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction. 2003;145:1051-7
- Lapointe N (see Rouleau et al). 2003;145:926-32
- Lappé JM (see Jackson et al). 2003;145:875-81
- Lapuerta P (see Wong et al). 2003;145:888-95
- Laron Z (see Feinberg et al). 2003;145:549-53
- Laskey WK (see Kizer et al). 2003;145:683-92
- Laster SB (see Marso et al). 2003;145:270-7
- Lau C (see Newman et al). 2003;145:430-7
- Leach D (see Aranda et al). 2003;145:324-9
- Leape LL, Weissman JS, Schneider EC, Piana RN, Gatsonis C, Epstein AM. Adherence to practice guidelines: the role of specialty society guidelines. 2003;145:19-26
- Leavitt B (see Nowicki et al). 2003;145:1058-62
- Lederman RJ (see Rajagopalan et al). 2003;145:1114-18
- Lee C-W (see Song et al). 2003;145:371-6
- Lee DP (see Fearon et al). 2003;145:882-7
- Lee KL (see Al-Khatib et al). 2003;145:515-21
- Lee MKY (see Resnic et al). 2003;145:42-6
- Lekston A (see Poloski et al). 2003;145:855-61
- Lengsfelder B (see Bonz et al). 2003;145:693-9
- Lenz K (see Mitrovic et al). 2003;145:e14
- Lessard D (see Spencer et al). 2003;145:500-7
- Levine RA (see Fox et al). 2003;145:730-6
- Lewis B (see Cotter et al). 2003;145:622-7
- Lewis MR (see Palmieri et al). 2003;145:467-74
- Liao L, Kong DF. Angiographic changes in vein grafts: stable surrogate or seductive siren? 2003;145:187-9 (Editorial)
- Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. 2003;145:459-66
- LIFE Study Investigators (see Oikarinen et al). 2003;145:919-25
- Liistro F (see Briguori et al). 2003;145:700-7

Limon J (see Gruchaa et al). 2003;145:125-31
 Lin H (see Yu et al). 2003;145:e23
 Lindqvist J (see Engdahl et al). 2003;145:826-33
 Lindsay J Jr (see Gruberg et al). 2003;145:529-34
 Linke A (see Gielen et al). 2003;145:e3
 LIPID Investigators (see Hague et al). 2003;145:643-51
 Lipshultz SE (see Benun et al). 2003;145:424-9
 Lipshultz SE (see Rivenes et al). 2003;145:716-23
 L'Italien GJ (see Wong et al). 2003;145:888-95
 Littmann L, Monroe MH, Kerns WP II, Svenson RH, Gallagher JJ. Brugada syndrome and "Brugada sign": clinical spectrum with a guide for the clinician. 2003;145:768-78 (Curriculum cardiol.)
 Liu-Stratton Y (see French et al). 2003;145:118-24
 Longaker RA (see Stoddard et al). 2003;145:676-82
 Lonn E (see Crystal et al). 2003;145:174-8 (Trial design)
 Lopez-Jimenez F (see Hellermann et al). 2003;145:742-8
 Lopez LM (see Aranda et al). 2003;145:324-9
 Lüderitz B (see Bauriedel et al). 2003;145:343-8
 Lukas MA (see Gheorghiadu et al). 2003;145:S60-1
 Lund M (see French et al). 2003;145:118-24
 Lupovitz S (see Blum et al). 2003;145:e7
 Lytle BL (see Pasquali et al). 2003;145:445-51

M

Macaya C (see Alfonso et al). 2003;145:254-61
 Macin SM (see Perna et al). 2003;145:e19 (Letter reply)
 Madjid M (see Casscells et al). 2003;145:813-20
 Madsen JK (see Jorgensen et al). 2003;145:e5
 Madsen TE (see Jackson et al). 2003;145:875-81
 Maggioni AP (see Vilella et al). 2003;145:475-83
 Magid DJ (see Rumsfeld et al). 2003;145:493-9
 Maia LN, Nicolau JC, Vitola JV, Santos M, Brandi JM, Joaquim MR, Baggi JM Jr, Cordeiro JA, de Godoy MF. Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. 2003;145:e27
 Malenka DJ (see Maynard et al). 2003;145:658-64
 Malenka DJ (see Piper et al). 2003;145:1022-9
 Mali WPTHM (see Bloemenkamp et al). 2003;145:409-17 (Progress cardiol.)
 Malinin AI, O'Connor CM, Dzhanashvili AI, Sane DC, Serebruany VL. Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 2003;145:397-403 (Curriculum cardiol.)
 Malinin AI (see Serebruany et al). 2003;145:636-42
 Malkin CJ (see Pugh et al). 2003;145:e11 (Letter)
 Manca C (see Metra et al). 2003;145:292-9
 Mangione A (see Hillis et al). 2003;145:88-94
 Maresh CM (see Pescatello et al). 2003;145:364-70
 Mark DB (see Batchelor et al). 2003;145:349-55
 Marks CRC (see Keteyian et al). 2003;145:912-18
 Marks DS (see Mitrovic et al). 2003;145:e14
 Markwood TT (see Kent et al). 2003;145:e8
 Marmor A (see Cotter et al). 2003;145:622-7
 Marroquin OC, Holubkov R, Edmundowicz D, Rickens C, Pohost G, Buchthal S, Pepine CJ, Sopko G, Sembrat RC, Meltzer CC, Reis SE. Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease: implications for clinical practice. 2003;145:628-35
 Marshall JJ (see Ghazzal et al). 2003;145:1006-12
 Marso SP, Giorgi LV, Johnson WL, Huber KC, Laster SB, Shelton CJ, McCallister BD, Coen MM, Rutherford BD. Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. 2003;145:270-7
 Marwick TH (see Fang and Marwick). 2003;145:904-11
 März W (see Taubert et al). 2003;145:285-91
 Massey KD (see Russell et al). 2003;145:179-86 (Trial design)
 Massie BM, Ansari MN. Specialty care for heart failure: does it improve outcomes? 2003;145:209-13 (Editorial)
 Massie BM (see Jain et al). 2003;145:83-17
 Mata P (see Mozas et al). 2003;145:999-1005
 Matetzky S (see Goldenberg et al). 2003;145:862-7
 Mathew JP (see Booth et al). 2003;145:1108-13
 Mathew TP (see Menown et al). 2003;145:986-92
 Mathur VS (see Adams et al). 2003;145:S34-46
 Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. 2003;145:330-3
 Matsumori A (see Sato et al). 2003;145:e18 (Letter)
 Mauri L, Reisman M, Buchbinder M, Popma JJ, Sharma SK, Cutlip DE, Ho KKL, Prpic R, Zimetbaum PJ, Kuntz RE. Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). 2003;145:847-54
 Mauro LM (see Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardiol.)
 Maynard C, Goss JR, Malenka DJ, Reisman M. Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program. 2003;145:658-64
 Mazeika P, Prasad N, Bui S, Seidlin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. 2003;145:1013-21
 McCabe CH (see Bahit et al). 2003;145:109-17
 McCabe CH (see Cotter et al). 2003;145:622-7
 McCallister BD (see Marso et al). 2003;145:270-7
 McCants CB (see Booth et al). 2003;145:1108-13
 McCrindle BW (see Baram et al). 2003;145:1063-70
 McDowell J (see French et al). 2003;145:118-24
 McGrath PD (see Piper et al). 2003;145:1022-9
 McGuire DK (see Abedin and McGuire). 2003;145:195-7 (Editorial)
 McKellar J (see Berry et al). 2003;145:1036-45
 Meekes CL (see Pescatello et al). 2003;145:364-70
 Mehler PS (see Havranek et al). 2003;145:993-8
 Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. 2003;145:821-5
 Mehta RH, Supiano MA, Oral H, Grossman PM, Montgomery DS, Smith MJ, Starling MR. Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. 2003;145:1078-85
 Meister AF (see Gurbel et al). 2003;145:239-47
 Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. 2003;145:36-41
 Meltzer CC (see Marroquin et al). 2003;145:628-35
 Mendelsohn FO (see Rajagopalan et al). 2003;145:1114-18
 Menown IBA, Mathew TP, Gracey HM, Nesbitt GS, Murray P, Young IS, Adgey AAJ. Prediction of Recurrent Events by D-dimer and Inflammatory markers in patients with normal Cardiac Troponin I (PREDICT) study. 2003;145:986-92
 Merry H (see Wood et al). 2003;145:806-12 (Progress cardiol.)
 Messere C (see Benun et al). 2003;145:424-9
 Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term β -blockade in patients with chronic heart failure: clinical correlates and prognostic significance. 2003;145:292-9
 Meyer J (see Ries et al). 2003;145:737-41
 Mezzani A, Corrà U, Bosimini E, Giordano A, Giannuzzi P. Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity. 2003;145:1102-7
 Michelson AD (see Furman et al). 2003;145:e6
 Michowitz Y (see Cotter et al). 2003;145:622-7
 Miki O (see Fujita et al). 2003;145:e16
 Milo O (see Cotter et al). 2003;145:622-7
 Miric M (see Mitrovic et al). 2003;145:e14
 Mitani H (see Nishioka et al). 2003;145:162-8

- Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukt A, Lenz K, Arens HA. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. 2003;145:e14
- Miwa K (see Fujita et al). 2003;145:e16
- Miyamoto A (see Fujita et al). 2003;145:e16
- Mizuno K (see Fujita et al). 2003;145:e16
- Möbius-Winkler S (see Gielen et al). 2003;145:e3
- Mohler E III (see Rajagopalan et al). 2003;145:1114-18
- Molitero DJ, Penn MS. Angioplasty, inflammation, and antiplatelet agents. 2003;145:563-6 (Editorial)
- Molitero DJ (see Quinn and Molitero). 2003;145:203-5 (Editorial)
- Moller JE, Egstrup K, Køber L, Poulsen SH, Nyvad O, Torp-Pedersen C. Prognostic importance of systolic and diastolic function after acute myocardial infarction. 2003;145:147-53
- Moller JE (see Sondergaard et al). 2003;145:e24
- Monroe MH (see Littmann et al). 2003;145:768-78 (Curriculum cardiol.)
- Monroe VS Jr (see Aranda et al). 2003;145:324-9
- Montgomery DS (see Mehta et al). 2003;145:1078-85
- Montorfano M (see Briguori et al). 2003;145:700-7
- Moodie DS (see Rivenes et al). 2003;145:716-23
- Mooser V (see Hauser et al). 2003;145:602-13
- Morioka D. Tranilast for restenosis: efficacious or not? 2003;145:e20 (Letter)
- Morris DC (see Ghazzal et al). 2003;145:1006-12
- Morrow DA, de Lemos JA. Assessing the success of fibrinolysis: can we let the interventionalist rest? 2003;145:380-2 (Editorial)
- Moyna NM (see Pescatello et al). 2003;145:364-70
- Mozas P, Castillo S, Reyes G, Tejedor D, Civeira F, García-Alvarez I, Puzo J, Cenarro A, Alonso R, Mata P, Pocovi M, Spanish group FH. Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. 2003;145:999-1005
- Mueller MN (see Furman et al). 2003;145:e6
- Muhlestein JB (see Jackson et al). 2003;145:875-81
- Munagala VK, Guduguntla V, Kasravi B, Cummings G, Gardin JM. Use of atropine in patients with chronotropic incompetence and poor exercise capacity during treadmill stress testing. 2003;145:1046-50
- Muncy DB (see Brodie et al). 2003;145:708-15
- Murakami Y (see Matsui et al). 2003;145:330-3
- Murphy SA (see Bahit et al). 2003;145:109-17
- Murray P (see Menown et al). 2003;145:986-92
- Myers J (see Partington et al). 2003;145:139-46
- N**
- Nagai T (see Nishioka et al). 2003;145:162-8
- Naghavi M (see Casscells et al). 2003;145:813-20
- Neil N (see Reynolds et al). 2003;145:334-42
- Nesbitt GS (see Menown et al). 2003;145:986-92
- Newman D, Lau C, Tang ASL, Irvine J, Paquette M, Woodend K, Dorian P, Gent M, Kerr C, Connolly SJ, CTOPP Investigators. Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. 2003;145:430-7
- Newman DM, Dorian P, Paquette M, Sulke N, Gold MR, Schwartzman DS, Schaaf K, Wood K, Johnson L, Worldwide Jewel AF AF-Only Investigators. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. 2003;145:841-6
- Newman MF (see Booth et al). 2003;145:1108-13
- Nicolau JC (see Maia et al). 2003;145:e27
- Nieminen MS (see Oikarinen et al). 2003;145:919-25
- Nishioka T, Mitani H, Uehata A, Hikita H, Nagai T, Katsushika S, Takase B, Isojima K, Ohsuzu F, Kurita A, Ohtomi S, Siegel RJ. Effect of infarcted myocardium on diagnostic accuracy of exercise echocardiography for detecting noninfarct-related coronary artery lesions. 2003;145:162-8

- Nissen SE (see Klingensmith et al). 2003;145:795-805 (Progress cardiol.)
- Nodari S (see Metra et al). 2003;145:292-9
- Northern New England Cardiovascular Disease Study Group (see Piper et al). 2003;145:1022-9
- Nowak A (see Gruchaa et al). 2003;145:125-31
- Nowicki ER, Weintraub RW, Birkmeyer NJO, Sanders JH, Dacey LJ, Lahey SJ, Leavitt B, Clough RA, Quinn RD, O'Connor GT. Mitral valve repair and replacement in northern New England. 2003;145:1058-62
- Nykanen DG (see Baram et al). 2003;145:1063-70
- Nyvad O (see Moller et al). 2003;145:147-53
- O**
- Oberman A (see Palmieri et al). 2003;145:1071-7
- O'Brien B (see Connolly et al). 2003;145:226-32
- Ochman K (see Gruchaa et al). 2003;145:125-31
- O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Frey A, Gheorghiadu M. RITZ-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). 2003;145:S58-9
- O'Connor CM, Gattis WA, Teerlink JR, Adams KF Jr, Gheorghiadu M. Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. 2003;145:S47-50
- O'Connor CM (see Bourque et al). 2003;145:758-67 (Curriculum cardiol.)
- O'Connor CM (see Felker and O'Connor). 2003;145:198-9 (Editorial)
- O'Connor CM (see Felker et al). 2003;145:S18-25
- O'Connor CM (see Gheorghiadu et al). 2003;145:S1-2, S51-4, S55-7, S60-1, S67-70
- O'Connor CM (see Hasdai et al). 2003;145:73-9
- O'Connor CM (see Malinin et al). 2003;145:397-403 (Curriculum cardiol.)
- O'Connor CM (see Zampino et al). 2003;145:S62-6
- O'Connor GT (see Nowicki et al). 2003;145:1058-62
- O'Connor GT (see Piper et al). 2003;145:1022-9
- Oddone EZ (see Indridason et al). 2003;145:300-9
- Oezaslan F (see Crystal et al). 2003;145:174-8 (Trial design)
- Oguogho A (see Palumbo et al). 2003;145:e12 (Letter)
- Öhlin H (see Tingberg et al). 2003;145:e1
- Ohman EM. Letter to the Editor. 2003;145:e26
- Ohman EM (see Al-Khatib et al). 2003;145:515-21
- Ohman EM (see Hasdai et al). 2003;145:73-9
- Ohno-Machado L (see Resnic et al). 2003;145:42-6
- Ohsuzu F (see Nishioka et al). 2003;145:162-8
- Ohtomi S (see Nishioka et al). 2003;145:162-8
- Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM, LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. 2003;145:919-25
- Okin PM (see Oikarinen et al). 2003;145:919-25
- Olin J (see Rajagopalan et al). 2003;145:1114-18
- Olshansky B (see Botkin et al). 2003;145:233-8
- O'Meara JR (see Piper et al). 2003;145:1022-9
- OPUS-TIMI 16 Investigators (see Cotter et al). 2003;145:622-7
- Oral D (see Akyürek et al). 2003;145:66-72
- Oral H (see Mehta et al). 2003;145:1078-85
- Orav EJ (see Benun et al). 2003;145:424-9
- Orlandi C (see Gheorghiadu et al). 2003;145:S51-4, S67-70
- Orlandi QG (see Ekery et al). 2003;145:896-902
- Ornato J (see Welsh et al). 2003;145:18 (Progress cardiol.)
- Oropeza ES, Cadena CN. New phenotype of familial dilated cardiomyopathy and conduction disorders. 2003;145:317-23
- O'Shea S (see Reddan et al). 2003;145:586-94 (Curriculum cardiol.)

P

- Packer M (see Rouleau et al). 2003;145:926-32
- Padmanabhan S, Silvet H, Amin J, Pai RG. Prognostic value of QT interval and QT dispersion in patients with left ventricular systolic dysfunction: results from a cohort of 2265 patients with an ejection fraction of $\leq 40\%$. 2003;145:132-8
- Pagliara V (see Berton et al). 2003;145:1094-101
- Pagnotta P (see Briguori et al). 2003;145:700-7
- Pai RG (see Padmanabhan et al). 2003;145:132-8
- Palatini P (see Berton et al). 2003;145:1094-101
- Palmer BF (see Drazner and Palmer). 2003;145:377-9 (Editorial)
- Palmieri R (see Berton et al). 2003;145:1094-101
- Palmieri V, Bella JN, Arnett DK, Oberman A, Kitzman DW, Hopkins PN, Rao DC, Roman MJ, Devereux RB. Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study. 2003;145:1071-7
- Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, Robbins DC, Fabsitz RR, Howard BV, Devereux RB. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. 2003;145:467-74
- Palumbo B, Oguogho A, Sinzinger H. Prostaglandin E₁ temporarily decreases adhesion molecules. 2003;145:e12 (Letter)
- Papademetriou V (see Oikarinen et al). 2003;145:919-25
- Paquette M (see Newman et al). 2003;145:430-7, 841-6
- Park S-J (see Song et al). 2003;145:371-6
- Park S-W (see Song et al). 2003;145:371-6
- Parker MA (see Ricciardi et al). 2003;145:522-8
- Parrinello G (see Licata et al). 2003;145:459-66
- Parrinello G (see Metra et al). 2003;145:292-9
- Partington S, Myers J, Cho S, Froelicher V, Chun S. Prevalence and prognostic value of exercise-induced ventricular arrhythmias. 2003;145:139-46
- Pasquali SK, Alexander KP, Coombs LP, Lytle BL, Peterson ED. Effect of cardiac rehabilitation on functional outcomes after coronary revascularization. 2003;145:445-51
- Pastor J (see Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardiol.)
- Patel AD, Iskandrian AE. Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris. 2003;145:952-61 (Curriculum cardiol.)
- Paterna S (see Licata et al). 2003;145:459-66
- Pauly DF (see Aranda et al). 2003;145:324-9
- PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. 2003;145:47-57
- Pearson TA (see Berry et al). 2003;145:1036-45
- Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group (see Rivenes et al). 2003;145:716-23
- Peleg A (see Blum et al). 2003;145:e7
- Pellikka PA (see Attenhofer Jost and Pellikka). 2003;145:938-40 (Editorial)
- Penn MS (see Moliterno and Penn). 2003;145:563-6 (Editorial)
- Pepine CJ (see Marroquin et al). 2003;145:628-35
- Pericak-Vance MA (see Hauser et al). 2003;145:602-13
- Perna ER, Macin SM, Farias EF, Jantus E. Measurements of serum cardiac troponin T in patients with heart failure. 2003;145:e19 (Letter reply)
- Person SD (see Ahmed et al). 2003;145:1086-93
- Pescatello LS, Bairos L, VanHeest JL, Maresch CM, Rodriguez NR, Moyna NM, DiPasquale C, Collins V, Meckes CL, Krueger L, Thompson PD. Postexercise hypotension differs between white and black women. 2003;145:364-70
- Petersen JL (see Dery et al). 2003;145:554-62 (Meetings)
- Peterson ED (see Batchelor et al). 2003;145:349-55
- Peterson ED (see Pasquali et al). 2003;145:445-51
- Phillips-Bute B (see Booth et al). 2003;145:1108-13

- Piana R (see Resnic et al). 2003;145:42-6
- Piana RN (see Leape et al). 2003;145:19-26
- Pianca S (see Berton et al). 2003;145:1094-101
- Picard MH (see Fox et al). 2003;145:730-6
- Pichard AD (see Gruberg et al). 2003;145:529-34
- Piessens J (see Dens et al). 2003;145:404-8 (Progress cardiol.)
- Pilote L (see Simpson et al). 2003;145:438-44
- Pimentel G (see Alfonso et al). 2003;145:254-61
- Pinnow EE (see Gruberg et al). 2003;145:529-34
- Piper WD, Malenka DJ, Ryan TJ Jr, Shubrooks SJ Jr, O'Connor GT, Robb JF, Farrell KL, Corliss MS, Hearne MJ, Kellett MA Jr, Watkins MW, Bradley WA, Hettleman BD, Silver TM, McGrath PD, O'Mears JR, Wennberg DE. Northern New England Cardiovascular Disease Study Group. Predicting vascular complications in percutaneous coronary interventions. 2003;145:1022-9
- Pirenne B (see Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)
- Pitt B (see Rouleau et al). 2003;145:926-32
- Plokker HWT (see ten Berg et al). 2003;145:58-65
- Plomondon ME (see Rumsfeld et al). 2003;145:493-9
- Pocovi M (see Mozas et al). 2003;145:999-1005
- Podgoreanu MV (see Booth et al). 2003;145:1108-13
- Pohorenc J (see French et al). 2003;145:118-24
- Polhost G (see Marroquin et al). 2003;145:628-35
- Poloski L, Gsior M, Wasilewski J, Wilczek K, Wnk A, Adamowicz-Czoch E, Sikora J, Lekston A, Zbik T, Gierlotka M, Wojnar R, Szkodzik J, Kondys M, Szygaa-Jurkiewicz B, Wok R, Zembala M. Outcomes of primary coronary angioplasty and angioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction. 2003;145:855-61
- Popma JJ (see Mauri et al). 2003;145:847-54
- Popma JJ (see Resnic et al). 2003;145:42-6
- Post CABG Investigators (see Knatterud et al). 2003;145:262-9
- Poston WSC (see Haddock et al). 2003;145:652-7
- Poulsen SH (see Moller et al). 2003;145:147-53
- Prasad N (see Mazeika et al). 2003;145:1013-21
- Preli RB (see Abdelhamed et al). 2003;145:e15
- Pressler M (see Rajagopalan et al). 2003;145:1114-18
- Pressler M (see Russell et al). 2003;145:179-86 (Trial design)
- Prpic R (see Mauri et al). 2003;145:847-54
- Pugh PJ, Malkin CJ, Channer KS. To the Editor. 2003;145:e11 (Letter)
- Pulsipher M (see Brodie et al). 2003;145:708-15
- Puzo J (see Mozas et al). 2003;145:999-1005
- Pyne DA (see Russell et al). 2003;145:179-86 (Trial design)

Q

- Quinn MJ, Moliterno DJ. Diabetes and percutaneous coronary intervention: the sweet smell of success? 2003;145:203-5 (Editorial)
- Quinn RD (see Nowicki et al). 2003;145:1058-62

R

- Raineri C (see Gavazzi et al). 2003;145:310-16
- Rainville B (see Brassard et al). 2003;145:e25
- Rajagopalan S, Mohler E III, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. 2003;145:1114-18
- Ramanathan K (see French et al). 2003;145:508-14
- Rao DC (see Palmieri et al). 2003;145:1071-7
- Rao SV (see Dery et al). 2003;145:554-62 (Meetings)
- Rasmussen H (see Rajagopalan et al). 2003;145:1114-18
- Ravid S (see Spencer et al). 2003;145:500-7
- Rea TD, Eisenberg MS. Long-term survival after resuscitation from cardiac arrest: cause for optimism and continued efforts. 2003;145:749-50 (Editorial)

- Rebeiz AG (see Dery et al). 2003;145:554-62 (Meetings)
- Redberg R. Coronary calcium: is racial profiling necessary? 2003; 145:579-81 (Editorial)
- Reddan D, Szczech LA, O'Shea S, Califf RM. Anticoagulation in acute cardiac care in patients with chronic kidney disease. 2003;145:586-94 (Curriculum cardiol.)
- Reeder GS (see Hellermann et al). 2003;145:742-8
- Reiber JHC (see Jorgensen et al). 2003;145:e5
- Reis SE (see Abdelhamed et al). 2003;145:e15
- Reis SE (see Marroquin et al). 2003;145:628-35
- Reisin L (see Cotter et al). 2003;145:622-7
- Reisman M (see Mauri et al). 2003;145:847-54
- Reisman M (see Maynard et al). 2003;145:658-64
- Resnic FS, Wainstein M, Lee MKY, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CDK, Popma JJ, Piana R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. 2003;145:426
- Reyes G (see Mozas et al). 2003;145:999-1005
- Reynolds MR, Neil N, Ho KKL, Berezin R, Cosgrove RS, Lager RA, Sirois C, Johnson RG, Cohen DJ. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience. 2003;145:334-42
- Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. 2003;145:522-8
- Richard H (see Simpson et al). 2003;145:438-44
- Richardt G (see Bonnemeyer et al). 2003;145:484-92
- Rickens C (see Marroquin et al). 2003;145:628-35
- Ries MW, Kampmann C, Rupprecht HJ, Hintereder G, Hafner G, Meyer J. Nickel release after implantation of the Amplatzer occluder. 2003;145:737-41
- RITZ-4 Investigators (see O'Connor et al). 2003;145:S58-9
- Rivadeneira D (see Ruiz et al). 2003;145:834-40
- Rivencs SM, Colan SD, Easley KA, Kaplan S, Jenkins KJ, Khan MN, Lai WW, Lipshultz SE, Moodie DS, Starc TJ, Sopko G, Zhang W, Bricker JT. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P²C² HIV) Multicenter study. 2003; 145:716-23
- Robb JF (see Piper et al). 2003;145:1022-9
- Robbins DC (see Palmieri et al). 2003;145:467-74
- Roberts RS (see Connolly et al). 2003;145:226-32
- Rodriguez NR (see Pescatello et al). 2003;145:364-70
- Roger VL (see Hellermann et al). 2003;145:742-8
- Rogers CDK (see Resnic et al). 2003;145:426
- Rojer A (see Tingberg et al). 2003;145:e1
- Roman MJ (see Palmieri et al). 2003;145:467-74, 1071-7
- Romanowski P (see Gruchaa et al). 2003;145:125-31
- Rosenbaum CG (see Khurana et al). 2003;145:724-9
- Rosenberg Y (see Knatterud et al). 2003;145:262-9
- Rosenqvist M (see Frykman et al). 2003;145:670-5
- Roses AD (see Hauser et al). 2003;145:602-13
- Roth A (see Goldenberg et al). 2003;145:862-7
- Rouleau JL, Pitt B, Dhalla NS, Dhalla KS, Swedberg K, Hansen MS, Stanton E, Lapointe N, Packer M. Canadian Prospective Randomized Flosequilnan Longevity Evaluation (PROFILE) Investigators. Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. 2003;145:926-32
- Rovner A (see Castello et al). 2003;145:535-41
- Ruiz GA, Calvar C, Hermes R, Rivadeneira D, Bengolea V, Chirife R, Tentori MC, Gelpi RJ. Insulin sensitivity in young women with vasovagal syncope. 2003;145:834-40
- Rumsfeld JS, Magid DJ, Plomondon ME, Sales AE, Grunwald GK, Every NR, Spertus JA. History of depression, angina, and quality of life after acute coronary syndromes. 2003;145:493-9
- Rupprecht HJ (see Ries et al). 2003;145:737-41

- Russell SD, Selaru P, Pyne DA, Ghazzi MM, Massey KD, Pressler M, Serikoff A, Coats AJS. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. 2003; 145:179-86 (Trial design)
- Rutherford BD (see Marso et al). 2003;145:270-7
- Ryan TJ. Percutaneous coronary interventions without on-site cardiac surgery: a stretch for much-needed evidence. 2003;145: 214-16 (Editorial)
- Ryan TJ Jr (see Piper et al). 2003;145:1022-9
- Rynkiewicz A (see Gruchaa et al). 2003;145:125-31

S

- Sabaté M (see Alfonso et al). 2003;145:254-61
- St Gibson W (see Lapeyre et al). 2003;145:1051-7
- Sales AE (see Rumsfeld et al). 2003;145:493-9
- Sanders JH (see Nowicki et al). 2003;145:1058-62
- Sanderson JE (see Yu et al). 2003;145:e23
- Sane DC (see Abdelhamed et al). 2003;145:e15
- Sane DC (see Malinin et al). 2003;145:397-403 (Curriculum cardiol.)
- Santoro E (see Vilella et al). 2003;145:475-83
- Santoro L (see Vilella et al). 2003;145:475-83
- Santos M (see Maia et al). 2003;145:e27
- Sarais C (see Briguori et al). 2003;145:700-7
- Satler LF (see Gruberg et al). 2003;145:529-34
- Sato Y, Taniguchi R, Yamada T, Matsumori A. Measurements of serum cardiac troponin T in patients with heart failure. 2003; 145:e18 (Letter)
- Sattler K (see Unverdorben et al). 2003;145:e17
- Saucedo J (see Rajagopalan et al). 2003;145:1114-18
- Sauer WH (see Kizer et al). 2003;145:683-92
- Saunamäki K (see Jorgensen et al). 2003;145:e5
- Sawchuk C (see Crystal et al). 2003;145:1748 (Trial design)
- Sayin T (see Akyurek et al). 2003;145:66-72
- Scandurra A (see Licata et al). 2003;145:459-66
- Scelsi L (see Gavazzi et al). 2003;145:310-16
- Schaaf K (see Newman et al). 2003;145:841-6
- Schachar FH (see Keteyian et al). 2003;145:912-18
- Scheinowitz M (see Feinberg et al). 2003;145:549-53
- Schleiffer T (see Taubert et al). 2003;145:285-91
- Schmidt S (see Hauser et al). 2003;145:602-13
- Schneider EC (see Leape et al). 2003;145:19-26
- Schneider JF (see Furman et al). 2003;145:e6
- Schneider M (see Bauriedel et al). 2003;145:343-8
- Schneider S (see Taubert et al). 2003;145:285-91
- Schneider TI, Höpp HW, Vlaho D, Wassmer G, Füssl R, Fassbender S, Wehr G, Konz KH, Späth F, Baer FM. Randomized comparison of mounted versus unmounted stents: the multicenter COMUS trial. 2003;145:e4
- Schoenhagen P (see Klingensmith et al). 2003;145:795-805 (Progress cardiol.)
- Schofield RS (see Aranda et al). 2003;145:324-9
- Scholz M (see Unverdorben et al). 2003;145:e17
- Schomaker U (see Kleber et al). 2003;145:614-21
- Schrier RW (see Havranek et al). 2003;145:993-8
- Schulenburg S (see Bonnemeyer et al). 2003;145:484-92
- Schuler G (see Gielen et al). 2003;145:e3
- Schwamm L (see Fox et al). 2003;145:730-6
- Schwartz JS (see Kizer et al). 2003;145:683-92
- Schwartz ML (see Benun et al). 2003;145:424-9
- Schwartz RS (see Kandzari et al). 2003;145:868-74
- Schwartzman DS (see Newman et al). 2003;145:841-6
- SCORES SVG Registry Investigators (see Kandzari et al). 2003;145: 868-74
- Scott WK (see Hauser et al). 2003;145:602-13
- Seferovic P (see Mitrovic et al). 2003;145:e14
- Seidlin PH (see Mazeika et al). 2003;145:1013-21
- Selaru P (see Russell et al). 2003;145:179-86 (Trial design)
- Sembrat RC (see Marroquin et al). 2003;145:628-35

- Semelhago L (see Crystal et al). 2003;145:174-8 (Trial design)
- Sennett C (see Brindis and Sennett). 2003;145:13-15 (Editorial)
- Serebruany VL, Malinin AI, Callahan KP, Binbrek A, Van de Werf F, Alexander JH, Granger CB, Gurbel PA. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) Platelet substudy. 2003;145:636-42
- Serebruany VL (see Gurbel et al). 2003;145:239-47
- Serebruany VL (see Malinin et al). 2003;145:397-403 (Curriculum cardiol.)
- Serikoff A (see Russell et al). 2003;145:179-86 (Trial design)
- Serio A (see Gavazzi et al). 2003;145:310-16
- Seto TB (see Taira et al). 2003;145:452-8
- Sgura F (see Briguori et al). 2003;145:700-7
- Shah MR (see O'Connor et al). 2003;145:558-9
- Shaneyfelt TM (see Ahmed et al). 2003;145:1086-93
- Shapira OM (see Ekery et al). 2003;145:896-902
- Sharma SK (see Mauri et al). 2003;145:847-54
- Shaw L (see Castello et al). 2003;145:535-41
- Shaw LK (see Bourque et al). 2003;145:758-67 (Curriculum cardiol.)
- Sheahan RG. Left atrial thrombus, transient ischemic attack, and atrial fibrillation: does left atrial thrombus predict? Does absence protect? 2003;145:582-5 (Editorial)
- Shelton CJ (see Marso et al). 2003;145:270-7
- Shemin RJ (see Ekery et al). 2003;145:896-902
- Shi Y-R (see Chou et al). 2003;145:169-73
- Shimada K (see Matsui et al). 2003;145:330-3
- Shragge B (see Crystal et al). 2003;145:174-8 (Trial design)
- Shubrooks SJ Jr (see Piper et al). 2003;145:1022-9
- Al-Shwafat KA, de Meester A, Pirenne B, Col JJ. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction. 2003;145:217-25 (Progress cardiol.)
- Siadat MS (see Casscells et al). 2003;145:813-20
- Siegel RJ (see Nishioka et al). 2003;145:162-8
- Siegrist R (see Taira et al). 2003;145:452-8
- Sikora J (see Poloski et al). 2003;145:855-61
- Silver TM (see Piper et al). 2003;145:1022-9
- Silvet H (see Padmanabhan et al). 2003;145:132-8
- Simes J (see Hague et al). 2003;145:643-51
- Simoons ML (see Hasdai et al). 2003;145:73-9
- Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. 2003;145:438-44
- Sims RV (see Ahmed et al). 2003;145:1086-93
- Singh KP (see Dery et al). 2003;145:554-62 (Meetings)
- Singh M (see Ting et al). 2003;145:278-84
- Singh P (see Stoddard et al). 2003;145:676-82
- Sinzinger H (see Palumbo et al). 2003;145:e12 (Letter)
- Sippel B (see Unverdorben et al). 2003;145:e17
- Sirois C (see Reynolds et al). 2003;145:334-42
- Sitafidis G (see Alexopoulos et al). 2003;145:542-8
- Sketch MH Jr (see Kandzari et al). 2003;145:868-74
- Skowasch D (see Bauriedel et al). 2003;145:343-8
- SMILE-2 Working Party (see Borghi et al). 2003;145:80-7
- Smith J (see Castello et al). 2003;145:535-41
- Smith MJ (see Mehta et al). 2003;145:1078-85
- Smith PK (see Booth et al). 2003;145:1108-13
- Sobiczewski W (see Gruchaa et al). 2003;145:125-31
- Sondergaard E, Moller JE, Egstrup K. Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia. 2003;145:e24
- Song J-K (see Song et al). 2003;145:371-6
- Song J-M, Kang D-H, Song J-K, Jeong Y-H, Lee C-W, Hong M-K, Kim J-J, Park S-W, Park S-J. Outcome of significant functional tricuspid regurgitation after percutaneous mitral valvuloplasty. 2003;145:371-6
- Sopko G (see Marroquin et al). 2003;145:628-35
- Sopko G (see Rivenes et al). 2003;145:716-23
- Späh F (see Schneider et al). 2003;145:e4
- Spanish group FH (see Mozas et al). 2003;145:999-1005
- Spanos V (see Briguori et al). 2003;145:700-7
- Spencer FA, Jabbar S, Lessard D, Yarzelski J, Ravid S, Zaleskas V, Hyder M, Gore JM, Goldberg RJ. Two-decade-long trends (1975-1997) in the incidence, hospitalization, and long-term death rates associated with complete heart block complicating acute myocardial infarction: a community-wide perspective. 2003;145:500-7
- Spertus J (see Haddock et al). 2003;145:652-7
- Spertus JA (see Rumsfeld et al). 2003;145:493-9
- Spinar J (see Mitrovic et al). 2003;145:e14
- Stafford RS. Feedback intervention to reduce routine electrocardiogram use in primary care. 2003;145:979-85
- Stanton E (see Rouleau et al). 2003;145:926-32
- Starck TJ (see Rivenes et al). 2003;145:716-23
- Starling MR (see Mehta et al). 2003;145:1078-85
- Stebbins AL (see Al-Khatib et al). 2003;145:515-21
- Stein PK (see Guo and Stein). 2003;145:779-86 (Curriculum cardiol.)
- Steinhubl S, Berger P. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? 2003;145:971-8 (Progress cardiol.)
- Stewart JT (see French et al). 2003;145:508-14
- Stewart RL (see Wood et al). 2003;145:806-12 (Progress cardiol.)
- Stoddard MF, Singh P, Dawn B, Longaker RA. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. 2003;145:676-82
- Strotmann J (see Bonz et al). 2003;145:693-9
- Stuckey TD (see Brodie et al). 2003;145:708-15
- Suadicani P (see Jeppesen et al). 2003;145:103-8
- Suddath WO (see Gruber et al). 2003;145:529-34
- Suissa S (see Brassard et al). 2003;145:e25
- Sulke N (see Newman et al). 2003;145:841-6
- Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. 2003;145:190-4 (Editorial)
- Supiano MA (see Mehta et al). 2003;145:1078-85
- Sutton TM (see French et al). 2003;145:118-24
- Suttorp MJ (see ten Berg et al). 2003;145:58-65
- Svenson RH (see Littmann et al). 2003;145:768-78 (Curriculum cardiol.)
- Swan J (see Castello et al). 2003;145:535-41
- Swedberg K (see Rouleau et al). 2003;145:926-32
- Szczzech LA (see Reddan et al). 2003;145:586-94 (Curriculum cardiol.)
- Szkodzinski J (see Poloski et al). 2003;145:855-61
- Szygwa-Jurkiewicz B (see Poloski et al). 2003;145:855-61
- Szymanski D (see French et al). 2003;145:118-24

T

- Taggart P (see Hillis et al). 2003;145:88-94
- Taira DA, Seto TB, Siegrist R, Cosgrove R, Berezin R, Cohen DJ. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. 2003;145:452-8
- Tajaddini A (see Klingensmith et al). 2003;145:795-805 (Progress cardiol.)
- Takase B (see Nishioka et al). 2003;145:162-8
- Tamai H. Tranilast for restenosis: efficacious or not? 2003;145:e21 (Letter reply)
- Tang ASL (see Newman et al). 2003;145:430-7
- Tang WHW (see Francis and Tang). 2003;145:200-2 (Editorial)
- Taniguchi R (see Sato et al). 2003;145:e18 (Letter)
- Tapson VF. Diagnosing and managing acute pulmonary embolism: role of cardiac troponins. 2003;145:751-3 (Editorial)
- Targoski R (see Gruchaa et al). 2003;145:125-31

- Taubert G, Winkelmann BR, Schleiffer T, März W, Winkler R, Gök R, Klein B, Schneider S, Boehm BO. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. 2003;145:285-91
- Tavazzi L (see Gavazzi et al). 2003;145:310-16
- Taylor AJ (see Kent et al). 2003;145:e8
- Taylor JE (see Haddock et al). 2003;145:652-7
- Tcheng JE (see Kandzari and Tcheng). 2003;145:9-12 (Editorial)
- Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. 2003;145:S26-33
- Teerlink JR (see Gheorghiadu et al). 2003;145:S67-70
- Teerlink JR (see O'Connor et al). 2003;145:S47-50
- Tejedor D (see Mozas et al). 2003;145:999-1005
- ten Berg JM, Kelder JC, Sutorp MJ, Verheugt FWA, Plokker HWT. A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS). 2003;145:58-65
- Tentori MC (see Ruiz et al). 2003;145:834-40
- Teoh K (see Crystal et al). 2003;145:174-8 (Trial design)
- Terrin ML (see Knatterud et al). 2003;145:262-9
- Tews K-H (see Unverdorben et al). 2003;145:e17
- Thakral G (see Wong et al). 2003;145:888-95
- Thaulow E (see Jorgensen and Thaulow). 2003;145:1030-5
- THE-PRINCE Study Group (see Kleber et al). 2003;145:614-21
- Theroux P (see French et al). 2003;145:508-14
- Thilen U (see Tingberg et al). 2003;145:e1
- Thompson PD (see Pescatello et al). 2003;145:364-70
- Thorpe KE (see Connolly et al). 2003;145:226-32
- Thuesen L (see Jorgensen et al). 2003;145:e5
- Timimi FK (see Ting et al). 2003;145:278-84
- Ting HH, Garratt KN, Singh M, Kjelsberg MA, Timimi FK, Cragun KT, Houlihan RJ, Boutchek KL, Crocker CH, Cusma JT, Wood DL, Holmes DR. Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up. 2003;145:278-84
- Tingberg E, Roijer A, Thilen U, Eskilsson J, Ohlin H. Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction. 2003;145:e1
- Todd DM, Yee R. Lessons from the implantable atrial defibrillator. 2003;145:569-70 (Editorial)
- Toivonen L (see Oikarinen et al). 2003;145:919-25
- Tölg R (see Bonnemeier et al). 2003;145:484-92
- Tomiyama H, Watanabe G, Yoshida H, Doba N, Yamashina A. Reduction of oxidative stress augments natriuretic effect of furosemide in moderate heart failure. 2003;145:e2
- Tonkin A (see Hague et al). 2003;145:643-51
- Topol EJ (see Al-Khatib et al). 2003;145:515-21
- Topol EJ (see Hasdai et al). 2003;145:73-9
- Topol EJ (see Yen and Topol). 2003;145:933-5 (Editorial)
- Torp-Pedersen C (see Moller et al). 2003;145:147-53
- Toulgaridis T (see Alexopoulos et al). 2003;145:542-8
- Trachtenberg JD (see Rajagopalan et al). 2003;145:1114-18
- Tsai F-J (see Chou et al). 2003;145:169-73
- Tsukahara R (see Fujita et al). 2003;145:e16
- Tu JV (see Austin et al). 2003;145:27-35
- Tuttolomondo A (see Licata et al). 2003;145:459-66
- Tuzcu EM (see Klingensmith et al). 2003;145:795-805 (Progress cardiol.)

U

- Uehata A (see Nishioka et al). 2003;145:162-8
- Unverdorben M, Sippel B, Degenhardt R, Sattler K, Fries R, Abt B, Wagner E, Koehler H, Daemgen G, Scholz M, Ibrahim H, Tews K-H, Hennen B, Berthold HK, Vallbracht C. Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome. 2003;145:e17

V

- Vagenakis AG (see Alexopoulos et al). 2003;145:542-8
- Vahanian A (see Hasdai et al). 2003;145:73-9
- Vallbracht C (see Unverdorben et al). 2003;145:e17
- Van de Water NS (see French et al). 2003;145:118-24
- Van de Werf F (see Hasdai et al). 2003;145:73-9
- Van de Werf F (see Serebruany et al). 2003;145:636-42
- van der Graaf Y (see Bloemenkamp et al). 2003;145:409-17 (Progress cardiol.)
- van Weert AWM (see Jorgensen et al). 2003;145:e5
- VanHeest JL (see Pescatello et al). 2003;145:364-70
- Vaseghi MF (see Casscells et al). 2003;145:813-20
- Velazquez EJ (see Bourque et al). 2003;145:758-67 (Curriculum cardiol.)
- Vered Z (see Cotter et al). 2003;145:622-7
- Verheugt FWA (see ten Berg et al). 2003;145:58-65
- Vigder F (see Blum et al). 2003;145:e7
- Viitasalo M (see Oikarinen et al). 2003;145:919-25
- Villadsen A (see Jorgensen et al). 2003;145:e5
- Villella A (see Villella et al). 2003;145:475-83
- Villella M, Villella A, Santoro L, Santoro E, Franzosi MG, Maggioni AP, GISSI-2 Investigators. Ergometric score systems after myocardial infarction: prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction. 2003;145:475-83
- Vince DG (see Klingensmith et al). 2003;145:795-805 (Progress cardiol.)
- Visseren FLJ (see Bloemenkamp et al). 2003;145:409-17 (Progress cardiol.)
- Vitola JV (see Maia et al). 2003;145:e27
- Vlaho D (see Schneider et al). 2003;145:e4
- Voelker W (see Bonz et al). 2003;145:693-9
- Vogel G (see Kleber et al). 2003;145:614-21

W

- Wachtell K (see Oikarinen et al). 2003;145:919-25
- Wagner E (see Unverdorben et al). 2003;145:e17
- Wainstein M (see Resnic et al). 2003;145:42-6
- Wainstein RV (see Resnic et al). 2003;145:42-6
- Waksman R (see Gruber et al). 2003;145:529-34
- Walker TC (see Aranda et al). 2003;145:324-9
- Wall TC (see Brodie et al). 2003;145:708-15
- Wasag B (see Gruchaa et al). 2003;145:125-31
- Wasilewski J (see Poloski et al). 2003;145:855-61
- Wassmer G (see Schneider et al). 2003;145:e4
- Watanabe G (see Tomiyama et al). 2003;145:e2
- Watkins MW (see Piper et al). 2003;145:1022-9
- Weber T (see Auer et al). 2003;145:e9 (Letter)
- Wehr G (see Schneider et al). 2003;145:e4
- Weinberg PM (see Fogel et al). 2003;145:154-61
- Weintraub RW (see Nowicki et al). 2003;145:1058-62
- Weintraub WS (see Ghazzal et al). 2003;145:1006-12
- Weissman JS (see Leape et al). 2003;145:19-26
- Weissman NJ (see Gruber et al). 2003;145:529-34
- Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. 2003;145:1-8 (Progress cardiol.)
- Wennberg DE (see Piper et al). 2003;145:1022-9
- Weston SA (see Hellermann et al). 2003;145:742-8
- Whellan DJ (see Bourque et al). 2003;145:758-67 (Curriculum cardiol.)
- White C (see Knatterud et al). 2003;145:262-9
- White HD (see Al-Khatib et al). 2003;145:515-21
- White HD (see French et al). 2003;145:118-24, 508-14
- White HD (see Wong et al). 2003;145:95-102
- Whyte JL (see Wong et al). 2003;145:888-95
- Wiegand UKH (see Bonnemeier et al). 2003;145:484-92

- Wilczek K (see Poloski et al). 2003;145:855-61
- Willenbrock R (see Mitrovic et al). 2003;145:e14
- Winkelmann BR (see Hauser et al). 2003;145:602-13
- Winkelmann BR (see Taubert et al). 2003;145:285-91
- Winkler R (see Taubert et al). 2003;145:285-91
- Witt C (see Kleber et al). 2003;145:614-21
- Wnk A (see Poloski et al). 2003;145:855-61
- Wojnar R (see Poloski et al). 2003;145:855-61
- Wok R (see Poloski et al). 2003;145:855-61
- Wong C-K, French JK, Gao W, White HD. Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase. 2003;145:95-102
- Wong ND, Thakral G, Franklin SS, L'Italien GJ, Jacobs MJ, Whyte JL, Lapuerta P. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. 2003;145:888-95
- Wood DL (see Ting et al). 2003;145:278-84
- Wood K (see Newman et al). 2003;145:841-6
- Wood MJ, Stewart RL, Merry H, Johnstone DE, Cox JL. Use of complementary and alternative medical therapies in patients with cardiovascular disease. 2003;145:806-12 (Progress cardiol.)
- Woodend K (see Newman et al). 2003;145:430-7
- Worldwide Jewel AF AF-Only Investigators (see Newman et al). 2003;145:841-6
- Wright AT (see Faulx et al). 2003;145:943-51 (Curriculum cardiol.)
- Wu C (see Hannan and Wu). 2003;145:571-4 (Editorial)

X

- Xhignesse M (see Brassard et al). 2003;145:e25

Y

- Yamada T (see Sato et al). 2003;145:e18 (Letter)
- Yamashina A (see Tomiyama et al). 2003;145:e2
- Yarzebski J (see Spencer et al). 2003;145:500-7
- Yee R (see Todd and Yee). 2003;145:569-70 (Editorial)
- Yen MH, Topol EJ. Atheromatous showers, periprocedural myocardial infarction, and fatality. 2003;145:933-5 (Editorial)
- Yeung AC (see Fearon et al). 2003;145:882-7
- Yock PG (see Fearon et al). 2003;145:882-7
- Yoshida H (see Tomiyama et al). 2003;145:e2
- Yoshioka T (see Matsui et al). 2003;145:330-3
- Young IS (see Menown et al). 2003;145:986-92
- Yu C-M, Lin H, Fung W-H, Zhang Q, Kong S-L, Sanderson JE. Comparison of acute changes in left ventricular volume, systolic and diastolic functions, and intraventricular synchronicity after biventricular and right ventricular pacing for heart failure. 2003;145:e23

Z

- Zahav YH (see Goldenberg et al). 2003;145:862-7
- Zaleskas V (see Spencer et al). 2003;145:500-7
- Zampino M, O'Connor CM, Gattis WA, Adams KF Jr, Gheorghade M. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of β -blocker therapy in patients with heart failure: a proposal for a trial. 2003;145:S62-6
- Zbik T (see Poloski et al). 2003;145:855-61
- Zembala M (see Poloski et al). 2003;145:855-61
- Zhang Q (see Yu et al). 2003;145:e23
- Zhang W (see Rivenes et al). 2003;145:716-23
- Zhao N (see Hillis et al). 2003;145:88-94
- Zimetbaum PJ (see Mauri et al). 2003;145:847-54
- Zimlichman R (see Cotter et al). 2003;145:622-7

Subject index*

A

Abciximab

Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention (Furman et al). 2003;145:e6

ACE inhibitors; see Angiotensin-converting enzyme inhibitors

Adrenergic beta-antagonists

β -Blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization (Jackson et al). 2003;145:875-81

β -Blockers and reverse remodeling: what are the implications? (Francis and Tang). 2003;145:200-2 (Editorial)

Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of β -blocker therapy in patients with heart failure: a proposal for a trial (Zampino et al). 2003;145:S62-6

Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the β -Blocker Length Of Stay (BLOS) study (Connolly et al). 2003;145:226-32

Marked improvement in left ventricular ejection fraction during long-term β -blockade in patients with chronic heart failure: clinical correlates and prognostic significance (Metra et al). 2003;145:292-9

Adrenolutin

Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure (Rouleau et al). 2003;145:926-32

Alteplase

Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tecteplase and lanoteplase during treatment of acute myocardial infarction (Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)

Effect of tecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) Platelet substudy (Serebruany et al). 2003;145:636-42

Alternative medicine; see Complementary therapies

American Heart Association

Highlights from the American Heart Association Annual Scientific Sessions 2002: November 17 to 20, 2002 (Dery et al). 2003;145:554-62 (Meetings)

Amlodipine

Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study (Jorgensen and Thaulow). 2003;145:1030-5

Amplatzer occluder

Nickel release after implantation of the Amplatzer occluder (Ries et al). 2003;145:737-41

Aneurysm

Altered coronary flow properties in diffuse coronary artery ectasia (Akyurek et al). 2003;145:66-72

Angina, unstable

High levels of circulating endothelial microparticles in patients with acute coronary syndromes (Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardiol.)

History of depression, angina, and quality of life after acute coronary syndromes (Rumsfeld et al). 2003;145:493-9

The Clopidogrel in Unstable Angina to Prevent Recurrent

Events (CURE) study: to what extent should the results be generalizable? (Gerschutz and Bhatt). 2003;145:595-601 (Progress cardiol.)

Angina pectoris; see also Chest pain

Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris (Patel and Iskandrian). 2003;145:952-61 (Curriculum cardiol.)

Angiogenesis factor

Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial (Rajagopalan et al). 2003;145:1114-18

Angiography

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes (Knatterud et al). 2003;145:262-9

Angiographic changes in vein grafts: stable surrogate or seductive siren? (Liao and Kong). 2003;145:187-9 (Editorial)

Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses (Casscells et al). 2003;145:813-20

Angioplasty

An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty (Dens et al). 2003;145:404-8 (Progress cardiol.)

Angioplasty, inflammation, and antiplatelet agents (Molitero and Penn). 2003;145:563-6 (Editorial)

Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism (Bonz et al). 2003;145:693-9

Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up (Ting et al). 2003;145:278-84

Percutaneous coronary interventions without on-site cardiac surgery: a stretch for much-needed evidence (Ryan). 2003;145:214-16 (Editorial)

Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction (Goldenberg et al). 2003;145:862-7

Angioplasty, balloon

A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS) (ten Berg et al). 2003;145:58-65

Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART) (Mauri et al). 2003;145:847-54

Angioplasty, transluminal, percutaneous coronary

Adherence to practice guidelines: the role of specialty society guidelines (Leape et al). 2003;145:19-26

Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study (Jorgensen and Thaulow). 2003;145:1030-5

Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty (Briguori et al). 2003;145:700-7

Outcomes of primary coronary angioplasty and angioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction (Poloski et al). 2003;145:855-61

Physician adherence to clinical practice guidelines: does it really matter? (Brindis and Sennett). 2003;145:13-15 (Editorial)

Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus (Mazeika et al). 2003;145:1013-21

Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials (PCAT Collaborators). 2003;145:47-57

*January, pp. 1-186; February, part 1, pp. 187-376; part 2, pp. 51-570; March, pp. 377-562; April, pp. 563-748; May pp. 749-932; June, pp. 933-1148.

Angiotensin-converting enzyme

Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and mitral valve prolapse syndrome (Chou et al). 2003;145:169-73

Angiotensin-converting enzyme inhibitors

Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry (Bauriedel et al). 2003;145:343-8

Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study (Borghi and Ambrosioni). 2003;145:80-7

What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? (Dickstein). 2003;145:754-7 (Editorial)

Antibiotics

Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension (Brassard et al). 2003;145:e25

Anticoagulants

Anticoagulation in acute cardiac care in patients with chronic kidney disease (Reddan et al). 2003;145:586-94 (Curriculum cardi.)

Antihypertensive agents

Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial (Havranek et al). 2003;145:993-8

Antiplatelet agents; see Platelet aggregation inhibitors**Aortic arch syndromes**

Flow volume asymmetry in the right aortic arch in children with magnetic resonance phase encoded velocity mapping (Fogel et al). 2003;145:154-61

Aortic valve diseases; see Heart valve diseases**Apolipoprotein E**

Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia (Mozas et al). 2003;145:999-1005

Arginine

No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia (Abdelhamed et al). 2003;145:e15

Arrhythmia

Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs (Botkin et al). 2003;145:233-8

Prevalence and prognostic value of exercise-induced ventricular arrhythmias (Partington et al). 2003;145:139-46

Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial (Al-Khatib et al). 2003;145:515-21

Temporal repolarization inhomogeneity and reperfusion arrhythmias in patients undergoing successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: impact of admission troponin T (Bonnemeier et al). 2003;145:484-92

Arteriosclerosis

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes (Knatterud et al). 2003;145:262-9

Angiographic changes in vein grafts: stable surrogate or seductive siren? (Liao and Kong). 2003;145:187-9 (Editorial)

Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry (Kandzari et al). 2003;145:868-74

Coronary artery calcification in black women and white women (Khurana et al). 2003;145:724-9

Coronary calcium: is racial profiling necessary? (Redberg). 2003;145:579-81 (Editorial)

Markers of inflammation and thrombosis: clues to plaque instability? (Kullo and Gersh). 2003;145:941-2 (Editorial)

Meta-analysis of sero-epidemiologic studies of the relation between *Chlamydia pneumoniae* and atherosclerosis: does study design influence results? (Bloemenkamp et al). 2003;145:409-17 (Progress cardi.)

Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses (Casscells et al). 2003;145:813-20

Prediction of Recurrent Events by D-dimer and Inflammatory markers in patients with normal Cardiac Troponin I (PRE-DICT) study (Menown et al). 2003;145:986-92

Prognostic significance of coronary artery calcium in asymptomatic subjects with usual cardiovascular risk (Alexopoulos et al). 2003;145:542-8

Ascorbic acid

Reduction of oxidative stress augments natriuretic effect of furosemide in moderate heart failure (Tomiya et al). 2003;145:e2

Aspirin

Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry (Bauriedel et al). 2003;145:343-8

Atherectomy, coronary

Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART) (Mauri et al). 2003;145:847-54

Atorvastatin

Effect of atorvastatin and pravastatin on serum C-reactive protein (Kent et al). 2003;145:e8

Atrial appendage

Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention (Crystal et al). 2003;145:174-8 (Trial design)

Atrial fibrillation; see also Arrhythmia

Atrial stunning: determinants and cellular mechanisms (Khan). 2003;145:787-94 (Progress cardi.)

Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the β -Blocker Length Of Stay (BLOS) study (Connolly et al). 2003;145:226-32

Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life (Newman et al). 2003;145:841-6

Left atrial thrombus, transient ischemic attack, and atrial fibrillation: does left atrial thrombus predict? Does absence protect? (Sheahan). 2003;145:582-5 (Editorial)

Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation (Stoddard et al). 2003;145:676-82

Lessons from the implantable atrial defibrillator (Todd and Yee). 2003;145:569-70 (Editorial)

Preventing stroke in patients with atrial fibrillation: current treatments and new concepts (Connolly). 2003;145:418-23 (Progress cardi.)

Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation (Kim et al). 2003;145:665-9

What characterizes episodes of atrial fibrillation requiring cardioversion? Experience from patients with an implantable atrial cardioverter (Frykman et al). 2003;145:670-5

Atrial natriuretic factor

Association of the *Scal* atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease (Gruchaa et al). 2003;145:125-31

Atropine

Atropine for inconclusive exercise tests: a beautiful solution or just cosmetics? (Attenhofer Jost and Pellikka). 2003;145:938-40 (Editorial)

Use of atropine in patients with chronotropic incompetence

and poor exercise capacity during treadmill stress testing (Munagala et al). 2003;145:1046-50

B

B-type natriuretic peptide; see Natriuretic peptide, brain

Bayes theorem

Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis (Berry et al). 2003;145:1036-45

Beta-blockers; see Adrenergic beta-antagonists

Biological markers

Biochemical and clinical predictors of long-term outcome in patients with nonspecific chest pain and nondiagnostic electrocardiograms (Hillis et al). 2003;145:88-94

Surrogate end points in heart failure trials (Gheorghiade et al). 2003;145:S67-70

ivalirudin

Anticoagulation in acute cardiac care in patients with chronic kidney disease (Reddan et al). 2003;145:586-94 (Curriculum cardiolo.)

Brachial artery

Detection of endothelial dysfunction with brachial artery ultrasound scanning (Faulx et al). 2003;145:943-51 (Curriculum cardiolo.)

Brugada syndrome

Brugada syndrome and "Brugada sign": clinical spectrum with a guide for the clinician (Littmann et al). 2003;145:768-78 (Curriculum cardiolo.)

C

C-reactive protein

C-Reactive protein in acute myocardial infarction: association with heart failure (Berton et al). 2003;145:1094-101

Effect of atorvastatin and pravastatin on serum C-reactive protein (Kent et al). 2003;145:e8

Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease (Almagor et al). 2003;145:248-53

CABG; see Coronary artery bypass

Calcium

Coronary artery calcification in black women and white women (Khurana et al). 2003;145:724-9

Coronary calcium: is racial profiling necessary? (Redberg). 2003;145:579-81 (Editorial)

Diastolic dysfunction after coronary artery bypass grafting: a frequent finding of clinical significance not influenced by intravenous calcium (Ekery et al). 2003;145:896-902

Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses (Casscells et al). 2003;145:813-20

Prognostic significance of coronary artery calcium in asymptomatic subjects with usual cardiovascular risk (Alexopoulos et al). 2003;145:542-8

Calcium-channel blockers

An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty (Dens et al). 2003;145:404-8 (Progress cardiolo.)

Candesartan cilexetil

Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure (Mitrovic et al). 2003;145:e14

Cardiac arrest; see Heart arrest

Cardiogenic shock; see Shock, cardiogenic

Cardiomyopathy, hypertrophic, familial

New phenotype of familial dilated cardiomyopathy and conduction disorders (Oropeza and Cadena). 2003;145:317-23

Cardiotonic agents

Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of β -blocker therapy in patients with heart failure: a proposal for a trial (Zampino et al). 2003;145:S62-6

Cardiovascular agents

Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization (Jain et al). 2003;145:S3-17

Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence (Simpson et al). 2003;145:438-44

Cardiovascular diseases

Chronic kidney disease as a cardiovascular risk factor (Best and Holmes). 2003;145:383-6 (Editorial)

Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study (Hauser et al). 2003;145:602-13

Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study (Palmieri et al). 2003;145:467-74

Use of complementary and alternative medical therapies in patients with cardiovascular disease (Wood et al). 2003;145:806-12 (Progress cardiolo.)

Cardiovascular system

Circadian rhythm in the cardiovascular system: chronocardiology (Guo and Stein). 2003;145:779-86 (Curriculum cardiolo.)

Cardioversion; see Defibrillators, implantable; Electric countershock

Carvedilol

Rationale and design of the Initiation Management PredischARGE: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study (Gheorghiade et al). 2003;145:S60-1

Catecholamines

Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure (Rouleau et al). 2003;145:926-32

Catheterization

Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada (Batchelor et al). 2003;145:349-55

Cell adhesion molecules

Prostaglandin E₂ temporarily decreases adhesion molecules (Palumbo et al) (Letter); (Gianetti and De Caterina) (Reply). 2003;145:e12, e13

Cerebrovascular accident

Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention (Crystal et al). 2003;145:174-8 (Trial design)

Left atrial thrombus, transient ischemic attack, and atrial fibrillation: does left atrial thrombus predict? Does absence protect? (Sheahan). 2003;145:582-5 (Editorial)

Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation (Stoddard et al). 2003;145:676-82

Preventing stroke in patients with atrial fibrillation: current treatments and new concepts (Connolly). 2003;145:418-23 (Progress cardiolo.)

Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study (Cotter et al). 2003;145:622-7

Chest pain; see also Angina, unstable; Angina pectoris

Biochemical and clinical predictors of long-term outcome in patients with nonspecific chest pain and nondiagnostic electrocardiograms (Hillis et al). 2003;145:88-94

Endothelium-independent coronary microvascular function: all

vessels are not created equally (Hasdai). 2003;145:567-8 (Editorial)

Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease: implications for clinical practice (Marroquin et al). 2003;145:628-35

Child

Cardiac management by pediatricians versus pediatric cardiologists in an inpatient academic center (Benun et al). 2003;145:424-9

Flow volume asymmetry in the right aortic arch in children with magnetic resonance phase encoded velocity mapping (Fogel et al). 2003;145:154-61

Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P²C² HIV) Multicenter study (Rivenes et al). 2003;145:716-23

Chlamydia pneumoniae

Meta-analysis of sero-epidemiologic studies of the relation between *Chlamydia pneumoniae* and atherosclerosis: does study design influence results? (Bloemenkamp et al). 2003;145:409-17 (Progress cardiol.)

Cholesterol, HDL; see Lipoproteins, HDL cholesterol

Circadian rhythm

Circadian rhythm in the cardiovascular system: chronocardiology (Guo and Stein). 2003;145:779-86 (Curriculum cardiol.)

Clinical practice guidelines; see Practice guidelines

Clinical trials

B-Type natriuretic peptide: from bench to bedside (Adams et al). 2003;145:S34-46

Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials (Taira et al). 2003;145:452-8

Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of β -blocker therapy in patients with heart failure: a proposal for a trial (Zampino et al). 2003;145:S62-6

Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure (O'Connor et al). 2003;145:S47-50

Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry (Bahit et al). 2003;145:109-17

Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure (Teerlink). 2003;145:S26-33

Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study (Gheorghiade et al). 2003;145:S60-1

Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVED-HF) (Gheorghiade et al). 2003;145:S55-7

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure (Gheorghiade et al). 2003;145:S51-4

Surrogate end points in heart failure trials (Gheorghiade et al). 2003;145:S67-70

Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Fourth Randomized Intravenous Tezosentan Study (RITZ-4) (O'Connor et al). 2003;145:S58-9

The management of decompensated heart failure resulting in hospitalization: proceedings from an expert meeting to review current concepts and to define future directions—Introduction (Gheorghiade et al). 2003;145:S1-2

Clopidogrel

Antiplatelet effects of angiotensin-converting enzyme inhibitors

compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry (Bauriedel et al). 2003;145:343-8

Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial (Gurbel et al). 2003;145:239-47

Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? (Malinin et al). 2003;145:397-403 (Curriculum cardiol.)

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? (Gerschütz and Bhatt). 2003;145:595-601 (Progress cardiol.)

Complementary therapies

Use of complementary and alternative medical therapies in patients with cardiovascular disease (Wood et al). 2003;145:806-12 (Progress cardiol.)

Congenital heart defects; see Heart defects, congenital

Congestive heart failure; see Heart failure, congestive

Conivaptan

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial (Russell et al). 2003;145:179-86 (Trial design)

Contrast media; see Radionuclide imaging

Coronary artery bypass

Adherence to practice guidelines: the role of specialty society guidelines (Leape et al). 2003;145:19-26

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes (Knatterud et al). 2003;145:262-9

Angiographic changes in vein grafts: stable surrogate or seductive siren? (Liao and Kong). 2003;145:187-9 (Editorial)

Chronic kidney disease as a cardiovascular risk factor (Best and Holmes). 2003;145:383-6 (Editorial)

Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry (Kandzari et al). 2003;145:868-74

Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience (Reynolds et al). 2003;145:334-42

Diastolic dysfunction after coronary artery bypass grafting: a frequent finding of clinical significance not influenced by intravenous calcium (Ekery et al). 2003;145:896-902

Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention (Gruberg et al). 2003;145:529-34

Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention (Crystal et al). 2003;145:174-8 (Trial design)

Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery (Booth et al). 2003;145:1108-13

Physician adherence to clinical practice guidelines: does it really matter? (Brindis and Sennett). 2003;145:13-15 (Editorial)

Coronary circulation

Altered coronary flow properties in diffuse coronary artery ectasia (Akyürek et al). 2003;145:66-72

Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions (Fearon et al). 2003;145:882-7

Home-based versus hospital-based exercise programs in patients with coronary artery disease: effects on coronary vasomotion (Gielen et al). 2003;145:e3

Coronary disease

Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis (Sullivan). 2003;145:190-4 (Editorial)

Association of the *Scal* atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease (Gruchaa et al). 2003;145:125-31

- Cytomegalovirus seropositivity, infectious burden, and coronary artery disease (Auer et al) (Letter); (Gattone) (Reply). 2003;145:e9, e10
- Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study (Hauser et al). 2003;145:602-13
- Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada (Batchelor et al). 2003;145:349-55
- Don't miss this opportunity: diagnosing diabetes (Abedin and McGuire). 2003;145:195-7 (Editorial)
- Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography (Taubert et al). 2003;145:285-91
- Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex (Wong et al). 2003;145:888-95
- Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study (Cotter et al). 2003;145:622-7
- Quality of life and time trade-off utility measures in patients with coronary artery disease (Melsop et al). 2003;145:36-41
- Coronary disease, diagnosis**
- Automated three-dimensional assessment of coronary artery anatomy with intravascular ultrasound scanning (Klingensmith et al). 2003;145:795-805 (Progress cardiol.)
- Prognostic significance of coronary artery calcium in asymptomatic subjects with usual cardiovascular risk (Alexopoulos et al). 2003;145:542-8
- Coronary disease, therapy**
- Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study (Hague et al). 2003;145:643-51
- Home-based versus hospital-based exercise programs in patients with coronary artery disease: effects on coronary vasomotion (Gielen et al). 2003;145:e3
- Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease (Almagor et al). 2003;145:248-53
- Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? (Bourque et al). 2003;145:758-67 (Curriculum cardiol.)
- To the Editor (Pugh et al). 2003;145:e11 (Letter)
- Coronary restenosis**
- A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS) (ten Berg et al). 2003;145:58-65
- An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty (Dens et al). 2003;145:404-8 (Progress cardiol.)
- β -Blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization (Jackson et al). 2003;145:875-81
- Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry (Kandzari et al). 2003;145:868-74
- Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART) (Mauri et al). 2003;145:847-54
- Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome (Unverdorben et al). 2003;145:e17
- Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT)—a randomized trial comparing a first-generation stent with a second-generation stent (Jorgensen et al). 2003;145:e5
- Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus (Mazeika et al). 2003;145:1013-21
- Predictors and implications of residual plaque burden after coronary stenting: an intravascular ultrasound study (Alfonso et al). 2003;145:254-61
- Randomized comparison of mounted versus unmounted stents: the multicenter COMUS trial (Schneider et al). 2003;145:e4
- Sargogrelate treatment reduces restenosis after coronary stenting (Fujita et al). 2003;145:e16
- Tranilast for restenosis: efficacious or not? (Morioka) (Letter); (Tamai) (Reply); (Holmes and Danoff) (Reply). 2003;145:e20, e21, e22
- What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? (Steinhuyl and Berger). 2003;145:971-8 (Progress cardiol.)
- Coronary stenosis**
- Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses (Casscells et al). 2003;145:813-20
- Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction (French et al). 2003;145:118-24
- Corrections**
- Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates (Warraich et al) (2002;143:1076-84). 2003;145:213
- Letter to the Editor (Ohman). 2003;145:e26
- Correspondence; see Letters to the Editor**
- Costs and cost analysis**
- Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience (Reynolds et al). 2003;145:334-42
- Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials (Taira et al). 2003;145:452-8
- Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions (Fearon et al). 2003;145:882-7
- Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs (Botkin et al). 2003;145:233-8
- Coumarins**
- A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS) (ten Berg et al). 2003;145:58-65
- Creatine kinase**
- Atheromatous showers, periprocedural myocardial infarction, and fatality (Yen and Topol). 2003;145:933-5 (Editorial)
- Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIIa antagonist era (Ghazzal et al). 2003;145:1006-12
- Troponin I elevation and cardiac events after percutaneous coronary intervention (Ricciardi et al). 2003;145:522-8
- Cytokines; see Inflammation mediators**
- Cytomegalovirus**
- Cytomegalovirus seropositivity, infectious burden, and coronary artery disease (Auer et al) (Letter); (Gattone) (Reply). 2003;145:e9, e10

Defibrillators, implantable

- Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life (Newman et al). 2003;145:841-6
- Lessons from the implantable atrial defibrillator (Todd and Yee). 2003;145:569-70 (Editorial)
- What characterizes episodes of atrial fibrillation requiring cardioversion? Experience from patients with an implantable atrial cardioverter (Frykman et al). 2003;145:670-5

Depression

- History of depression, angina, and quality of life after acute coronary syndromes (Rumsfeld et al). 2003;145:493-9

Diabetes mellitus

- Diabetes and percutaneous coronary intervention: the sweet smell of success? (Quinn and Moliterno). 2003;145:203-5 (Editorial)
- Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years (Marso et al). 2003;145:270-7
- Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial (Havranek et al). 2003;145:993-8
- Don't miss this opportunity: diagnosing diabetes (Abedin and McGuire). 2003;145:195-7 (Editorial)
- Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus (Mazeika et al). 2003;145:1013-21
- Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography (Taubert et al). 2003;145:285-91

Diet and dietary supplements

- Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia (Sondergaard et al). 2003;145:e24
- No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia (Abdelhamed et al). 2003;145:e15
- Use of complementary and alternative medical therapies in patients with cardiovascular disease (Wood et al). 2003;145:806-12 (Progress cardiol.)

Diuretics

- Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization (Jain et al). 2003;145:S3-17

Dobutamine

- A bridge for the 21st century in heart transplantation? (Felder and O'Connor). 2003;145:198-9 (Editorial)
- Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial (Aranda et al). 2003;145:324-9
- Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVED-HF) (Gheorghiade et al). 2003;145:S55-7

Dose-response relationship, drug

- Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis (Berry et al). 2003;145:1036-45

Dyslipidemia; see Hypercholesterolemia and hyperlipidemia**Dyspnea**

- Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure (Teerlink). 2003;145:S26-33

E**Echocardiography**

- Effect of infarcted myocardium on diagnostic accuracy of exer-

cise echocardiography for detecting noninfarct-related coronary artery lesions (Nishioka et al). 2003;145:162-8

Efficacy and time-efficiency of a "sonographer-driven" contrast echocardiography protocol in a high-volume echocardiography laboratory (Castello et al). 2003;145:535-41

Interatrial septal mobility predicts larger shunts across patent foramen ovals: an analysis with transmitral Doppler scanning (Fox et al). 2003;145:730-6

Prognostic value of QT interval and QT dispersion in patients with left ventricular systolic dysfunction: results from a cohort of 2265 patients with an ejection fraction of $\leq 40\%$ (Padmanabhan et al). 2003;145:132-8

Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study (Oikarinen et al). 2003;145:919-25

Editorials

A bridge for the 21st century in heart transplantation? (Felder and O'Connor). 2003;145:198-9

Angiographic changes in vein grafts: stable surrogate or seductive siren? (Liao and Kong). 2003;145:187-9

Angioplasty, inflammation, and antiplatelet agents (Moliterno and Penn). 2003;145:563-6

Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis (Sullivan). 2003;145:190-4

Assessing quality and outcomes for percutaneous coronary intervention: choosing statistical models, outcomes, time periods, and patient populations (Hannan and Wu). 2003;145:571-4

Assessing the success of fibrinolysis: can we let the interventionist rest? (Morrow and de Lemos). 2003;145:380-2

Atheromatous showers, periprocedural myocardial infarction, and fatality (Yen and Topol). 2003;145:933-5

Atropine for inconclusive exercise tests: a beautiful solution or just cosmetics? (Attenhofer Jost and Pellikka). 2003;145:938-40

β -Blockers and reverse remodeling: what are the implications? (Francis and Tang). 2003;145:200-2

Chronic kidney disease as a cardiovascular risk factor (Best and Holmes). 2003;145:383-6

Coronary calcium: is racial profiling necessary? (Redberg). 2003;145:579-81

Diabetes and percutaneous coronary intervention: the sweet smell of success? (Quinn and Moliterno). 2003;145:203-5

Diagnosing and managing acute pulmonary embolism: role of cardiac troponins (Tapson). 2003;145:751-3

Don't miss this opportunity: diagnosing diabetes (Abedin and McGuire). 2003;145:195-7

Double negatives (Kandzari and Tchong). 2003;145:9-12

Endothelium-independent coronary microvascular function: all vessels are not created equally (Hasdai). 2003;145:567-8

Heart failure with preserved systolic function after myocardial infarction: a growing burden? (Ghali). 2003;145:575-8

Hierarchical modeling: its time has come (DeLong). 2003;145:16-18

Hypertonic saline: a novel therapy for advanced heart failure? (Drazner and Palmer). 2003;145:377-9

Impacting the use of the screening electrocardiogram (Cuffe). 2003;145:936-7

Left atrial thrombus, transient ischemic attack, and atrial fibrillation: does left atrial thrombus predict? Does absence protect? (Sheahan). 2003;145:582-5

Lessons from the implantable atrial defibrillator (Todd and Yee). 2003;145:569-70

Long-term survival after resuscitation from cardiac arrest: cause for optimism and continued efforts (Rea and Eisenberg). 2003;145:749-50

Markers of inflammation and thrombosis: clues to plaque instability? (Kullo and Gersh). 2003;145:941-2

Percutaneous coronary interventions without on-site cardiac surgery: a stretch for much-needed evidence (Ryan). 2003;145:214-16

Physician adherence to clinical practice guidelines: does it really matter? (Brindis and Sennett). 2003;145:13-15

Specialty care for heart failure: does it improve outcomes? (Massie and Ansari). 2003;145:209-13

The finer points of race and hypertension (Frazier and Alexander). 2003;145:206-8

What did we learn from the OPTIMAAL trial? What can we expect from VALLANT? (Dickstein). 2003;145:754-7

Electric countershock

Atrial stunning: determinants and cellular mechanisms (Khan). 2003;145:787-94 (Progress cardiol.)

Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life (Newman et al). 2003;145:841-6

Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs (Botkin et al). 2003;145:233-8

Electrocardiography

Brugada syndrome and "Brugada sign": clinical spectrum with a guide for the clinician (Littmann et al). 2003;145:768-78 (Curriculum cardiol.)

Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial (Havranek et al). 2003;145:993-8

Feedback intervention to reduce routine electrocardiogram use in primary care (Stafford). 2003;145:979-85

Impacting the use of the screening electrocardiogram (Cuffe). 2003;145:936-7 (Editorial)

Prognostic value of QT interval and QT dispersion in patients with left ventricular systolic dysfunction: results from a cohort of 2265 patients with an ejection fraction of $\leq 40\%$ (Padmanabhan et al). 2003;145:132-8

Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study (Oikarinen et al). 2003;145:919-25

Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P²C² HIV) Multicenter study (Rivenes et al). 2003;145:716-23

Embolism and thrombosis

Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism (Mehta et al). 2003;145:821-5

Diagnosing and managing acute pulmonary embolism: role of cardiac troponins (Tapon). 2003;145:751-3 (Editorial)

Interatrial septal mobility predicts larger shunts across patent foramen ovales: an analysis with transmittal Doppler scanning (Fox et al). 2003;145:730-6

Left atrial thrombus, transient ischemic attack, and atrial fibrillation: does left atrial thrombus predict? Does absence protect? (Sheahan). 2003;145:582-5 (Editorial)

Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation (Stoddard et al). 2003;145:676-82

Markers of inflammation and thrombosis: clues to plaque instability? (Kullo and Gersh). 2003;145:941-2 (Editorial)

Prediction of Recurrent Events by D-dimer and Inflammatory markers in patients with normal Cardiac Troponin I (PRE-DICT) study (Menown et al). 2003;145:986-92

Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease (Kleber et al). 2003;145:614-21

Enalapril

Prospective evaluation comparing the effects of enalapril and

losartan in left ventricular remodeling after acute myocardial infarction (Maia et al). 2003;145:e27

Endothelial growth factors

Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial (Rajagopalan et al). 2003;145:1114-18

Endothelium, vascular

Detection of endothelial dysfunction with brachial artery ultrasound scanning (Faulx et al). 2003;145:943-51 (Curriculum cardiol.)

High levels of circulating endothelial microparticles in patients with acute coronary syndromes (Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardiol.)

Enoxaparin

Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease (Kleber et al). 2003;145:614-21

Ergometry

Ergometric score systems after myocardial infarction: prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction (Vilella et al). 2003;145:475-83

Estrogens

Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis (Sullivan). 2003;145:190-4 (Editorial)

Exercise

Contribution of peak respiratory exchange ratio to peak VO₂ prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity (Mezzani et al). 2003;145:1102-7

Differential effects of exercise training in men and women with chronic heart failure (Keteyian et al). 2003;145:912-18

Home-based versus hospital-based exercise programs in patients with coronary artery disease: effects on coronary vasomotion (Gielen et al). 2003;145:e3

Mechanisms of exercise training in patients with heart failure (Fang and Marwick). 2003;145:904-11

Postexercise hypotension differs between white and black women (Pescatello et al). 2003;145:364-70

The finer points of race and hypertension (Frazier and Alexander). 2003;145:206-8 (Editorial)

Exercise test

Atropine for inconclusive exercise tests: a beautiful solution or just cosmetics? (Attenhofer Jost and Pellikka). 2003;145:938-40 (Editorial)

Comparison of the predischARGE exercise thallium-201 perfusion defect after myocardial infarction with myocardium at risk measured during acute infarction with technetium-99m sestamibi imaging (Lapeyre et al). 2003;145:357-63

Effect of infarcted myocardium on diagnostic accuracy of exercise echocardiography for detecting noninfarct-related coronary artery lesions (Nishioka et al). 2003;145:162-8

Ergometric score systems after myocardial infarction: prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction (Vilella et al). 2003;145:475-83

Prevalence and prognostic value of exercise-induced ventricular arrhythmias (Partington et al). 2003;145:139-46

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial (Russell et al). 2003;145:179-86 (Trial design)

Use of atropine in patients with chronotropic incompetence and poor exercise capacity during treadmill stress testing (Munagala et al). 2003;145:1046-50

F**Feedback**

Feedback intervention to reduce routine electrocardiogram use in primary care (Stafford). 2003;145:979-85

Impacting the use of the screening electrocardiogram (Cuffe). 2003;145:936-7 (Editorial)

Fibrinogen

Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study (Palmieri et al). 2003;145:467-74

Fibrinolytic therapy; see Thrombolytic therapy**Fractional flow reserve**

Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions (Fearon et al). 2003;145:882-7

Furosemide

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects (Licata et al). 2003;145:459-66

Hypertonic saline: a novel therapy for advanced heart failure? (Drazner and Palmer). 2003;145:377-9 (Editorial)

Reduction of oxidative stress augments natriuretic effect of furosemide in moderate heart failure (Tomiyama et al). 2003;145:e2

G**Genetics**

Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia (Mozas et al). 2003;145:999-1005

Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and mitral valve prolapse syndrome (Chou et al). 2003;145:169-73

Association of the *Scal* atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease (Gruchaa et al). 2003;145:125-31

Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study (Hauser et al). 2003;145:602-13

New phenotype of familial dilated cardiomyopathy and conduction disorders (Oropeza and Cadena). 2003;145:317-23

Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction (French et al). 2003;145:118-24

Glycoprotein IIb/IIIa receptor antagonists; see Platelet aggregation inhibitors**Growth hormone**

Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age (Feinberg et al). 2003;145:549-53

H**HDL cholesterol; see Lipoproteins, HDL cholesterol****Heart arrest**

Brugada syndrome and "Brugada sign": clinical spectrum with a guide for the clinician (Littmann et al). 2003;145:768-78 (Curriculum cardi.)

Long-term survival after resuscitation from cardiac arrest: cause for optimism and continued efforts (Rea and Eisenberg). 2003;145:749-50 (Editorial)

Time trends in long-term mortality after out-of-hospital cardiac arrest, 1980 to 1998, and predictors for death (Engdahl et al). 2003;145:826-33

Heart block

New phenotype of familial dilated cardiomyopathy and conduction disorders (Oropeza and Cadena). 2003;145:317-23

Two-decade-long trends (1975-1997) in the incidence, hospitalization, and long-term death rates associated with complete heart block complicating acute myocardial infarction: a community-wide perspective (Spencer et al). 2003;145:500-7

Heart defects, congenital

Cardiac management by pediatricians versus pediatric cardiologists in an inpatient academic center (Benun et al). 2003;145:424-9

Flow volume asymmetry in the right aortic arch in children with magnetic resonance phase encoded velocity mapping (Fogel et al). 2003;145:154-61

Heart failure, congestive

C-Reactive protein in acute myocardial infarction: association with heart failure (Berton et al). 2003;145:1094-101

Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials (Hasdai et al). 2003;145:73-9

Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community (Hellermann et al). 2003;145:742-8

Heart failure with preserved systolic function after myocardial infarction: a growing burden? (Ghali). 2003;145:575-8 (Editorial)

Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? (Malinin et al). 2003;145:397-403 (Curriculum cardi.)

Heart failure, congestive, decompensated

B-Type natriuretic peptide: from bench to bedside (Adams et al). 2003;145:S34-46

Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of β -blocker therapy in patients with heart failure: a proposal for a trial (Zampino et al). 2003;145:S62-6

Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization (Jain et al). 2003;145:S3-17

Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure (O'Connor et al). 2003;145:S47-50

Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure (Teerlink). 2003;145:S26-33

Rationale and design of the Initiation Management Pre-discharge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study (Gheorghiad et al). 2003;145:S60-1

Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVED-HF) (Gheorghiad et al). 2003;145:S55-7

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure (Gheorghiad et al). 2003;145:S51-4

Surrogate end points in heart failure trials (Gheorghiad et al). 2003;145:S67-70

Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4) (O'Connor et al). 2003;145:S58-9

The management of decompensated heart failure resulting in hospitalization: proceedings from an expert meeting to review current concepts and to define future directions—Introduction (Gheorghiad et al). 2003;145:S1-2

The problem of decompensated heart failure: nomenclature, classification, and risk stratification (Felker et al). 2003;145:S18-25

Heart failure, congestive, drug therapy

Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in

- patients with congestive heart failure (Mitrovic et al). 2003;145:e14
- β -Blockers and reverse remodeling: what are the implications? (Francis and Tang). 2003;145:200-2 (Editorial)
- Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects (Licata et al). 2003;145:459-66
- Hypertonic saline: a novel therapy for advanced heart failure? (Drazner and Palmer). 2003;145:377-9 (Editorial)
- Marked improvement in left ventricular ejection fraction during long-term β -blockade in patients with chronic heart failure: clinical correlates and prognostic significance (Metra et al). 2003;145:292-9
- Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial (Russell et al). 2003;145:179-86 (Trial design)
- Reduction of oxidative stress augments natriuretic effect of furosemide in moderate heart failure (Tomiya et al). 2003;145:e2
- Heart failure, congestive, prognosis**
- Contribution of peak respiratory exchange ratio to peak VO₂ prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity (Mezzani et al). 2003;145:1102-7
- Measurements of serum cardiac troponin T in patients with heart failure (Sato et al) (Letter); (Perna et al) (Reply). 2003;145:e18, e19
- Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure (Rouleau et al). 2003;145:926-32
- Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension (Gavazzi et al). 2003;145:310-16
- Heart failure, congestive, therapy**
- Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care (Ahmed et al). 2003;145:1086-93
- Comparison of acute changes in left ventricular volume, systolic and diastolic functions, and intraventricular synchronicity after biventricular and right ventricular pacing for heart failure (Yu et al). 2003;145:e23
- Differential effects of exercise training in men and women with chronic heart failure (Keteyian et al). 2003;145:912-18
- Is specialty care associated with improved survival of patients with congestive heart failure? (Indridason et al). 2003;145:300-9
- Mechanisms of exercise training in patients with heart failure (Fang and Marwick). 2003;145:90-11
- Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? (Bourque et al). 2003;145:758-67 (Curriculum cardi.)
- Specialty care for heart failure: does it improve outcomes? (Massie and Ansari). 2003;145:209-13 (Editorial)
- Heart septal defects, atrial**
- Interatrial septal mobility predicts larger shunts across patent foramen ovales: an analysis with transmittal Doppler scanning (Fox et al). 2003;145:730-6
- Heart transplantation**
- A bridge for the 21st century in heart transplantation? (Felker and O'Connor). 2003;145:198-9 (Editorial)
- Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial (Aranda et al). 2003;145:324-9
- Heart valve diseases**
- Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and mitral valve prolapse syndrome (Chou et al). 2003;145:169-73
- Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study (Palmieri et al). 2003;145:1071-7
- Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation (Mehta et al). 2003;145:1078-85
- Mitral valve repair and replacement in northern New England (Nowicki et al). 2003;145:1058-62
- Outcome of significant functional tricuspid regurgitation after percutaneous mitral valvuloplasty (Song et al). 2003;145:371-6
- Outcomes of uncomplicated aortic valve stenosis presenting in infants (Baram et al). 2003;145:1063-70
- Heparin**
- Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease (Kleber et al). 2003;145:614-21
- Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation (Kim et al). 2003;145:665-9
- Hormone replacement therapy**
- Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age (Feinberg et al). 2003;145:549-53
- Hospitals, community**
- Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up (Ting et al). 2003;145:278-84
- Percutaneous coronary interventions without on-site cardiac surgery: a stretch for much-needed evidence (Ryan). 2003;145:214-16 (Editorial)
- Hydroxymethylglutaryl-CoA reductase inhibitors**
- Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis (Berry et al). 2003;145:1036-45
- Effect of atorvastatin and pravastatin on serum C-reactive protein (Kent et al). 2003;145:e8
- Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia (Sondergaard et al). 2003;145:e24
- Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study (Hague et al). 2003;145:643-51
- Treating dyslipidemia with statins: the risk-benefit profile (Clark). 2003;145:387-96 (Curriculum cardi.)
- Hypercholesterolemia and hyperlipidemia**
- Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia (Mozas et al). 2003;145:999-1005
- Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia (Sondergaard et al). 2003;145:e24
- Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia (Blum et al). 2003;145:e7
- No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia (Abdelhamed et al). 2003;145:e15
- Treating dyslipidemia with statins: the risk-benefit profile (Clark). 2003;145:387-96 (Curriculum cardi.)
- Hypertension**
- Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension (Brassard et al). 2003;145:e25

Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study (Palmieri et al). 2003;145:1071-7

Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial (Havranek et al). 2003;145:993-8

Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex (Wong et al). 2003;145:888-95

Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study (Oikarinen et al). 2003;145:919-25

The finer points of race and hypertension (Frazier and Alexander). 2003;145:206-8 (Editorial)

Hypertension, pulmonary

Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension (Gavazzi et al). 2003;145:310-16

Hypertrophy, left ventricular

Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study (Oikarinen et al). 2003;145:919-25

Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P²C² HIV) Multicenter study (Rivenes et al). 2003;145:716-23

Hypotension

Postexercise hypotension differs between white and black women (Pescatello et al). 2003;145:364-70

I

Imaging, three-dimensional

Automated three-dimensional assessment of coronary artery anatomy with intravascular ultrasound scanning (Klingensmith et al). 2003;145:795-805 (Progress cardiol.)

Infant

Outcomes of uncomplicated aortic valve stenosis presenting in infants (Baram et al). 2003;145:1063-70

Inflammation mediators

Angioplasty, inflammation, and antiplatelet agents (Molitero and Penn). 2003;145:563-6 (Editorial)

Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism (Bonz et al). 2003;145:693-9

Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia (Blum et al). 2003;145:e7

Markers of inflammation and thrombosis: clues to plaque instability? (Kullo and Gersh). 2003;145:941-2 (Editorial)

Prediction of Recurrent Events by D-dimer and Inflammatory markers in patients with normal Cardiac Troponin I (PRE-DICT) study (Menown et al). 2003;145:986-92

Inotropic agents; see Cardiotonic agents

Insulin

Insulin sensitivity in young women with vasovagal syncope (Ruiz et al). 2003;145:834-40

Intra-aortic balloon pumping

Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty (Briguori et al). 2003;145:700-7

Iron

Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis (Sullivan). 2003;145:190-4 (Editorial)

Ischemic heart disease; see Myocardial ischemia

Isosorbide

Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction (Tingberg et al). 2003;145:e1

K

Kidney failure

Anticoagulation in acute cardiac care in patients with chronic kidney disease (Reddan et al). 2003;145:586-94 (Curriculum cardiol.)

Chronic kidney disease as a cardiovascular risk factor (Best and Holmes). 2003;145:383-6 (Editorial)

Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention (Gruber et al). 2003;145:529-34

L

Letters to the Editor

Cytomegalovirus seropositivity, infectious burden, and coronary artery disease (Auer et al) (Letter); (Gattone) (Reply). 2003;145:e9, e10

Letter to the Editor (Ohman). 2003;145:e26

Measurements of serum cardiac troponin T in patients with heart failure (Sato et al) (Letter); (Perna et al) (Reply). 2003;145:e18, e19

To the Editor (Pugh et al). 2003;145:e11

Tranilast for restenosis: efficacious or not? (Morioka) (Letter); (Tamai) (Reply); (Holmes and Danoff) (Reply). 2003;145:e20, e21, e22

Leukocyte count

Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase (Wong et al). 2003;145:95-102

Lipoproteins, HDL cholesterol

High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease (Jeppesen et al). 2003;145:103-8

Lisinopril

Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study (Borghesi and Ambrosioni). 2003;145:80-7

Losartan

Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction (Maia et al). 2003;145:e27

What did we learn from the OPTIMAAL trial? What can we expect from VALLANT? (Dickstein). 2003;145:754-7 (Editorial)

M

Magnesium

Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery (Booth et al). 2003;145:1108-13

Magnetic resonance imaging

Flow volume asymmetry in the right aortic arch in children with magnetic resonance phase encoded velocity mapping (Fogel et al). 2003;145:154-61

Metoprolol

Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the β -Blocker Length Of Stay (BLOS) study (Connolly et al). 2003;145:226-32

Microcirculation

Endothelium-independent coronary microvascular function: all vessels are not created equally (Hasdai). 2003;145:567-8 (Editorial)

Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease: implications for clinical practice (Marroquin et al). 2003;145:628-35

Milrinone

A bridge for the 21st century in heart transplantation? (Felker and O'Connor). 2003;145:198-9 (Editorial)

Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial (Aranda et al). 2003;145:324-9

Mitral valve diseases; see Heart valve diseases

Models, statistical

Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program (Maynard et al). 2003;145:658-64

Assessing quality and outcomes for percutaneous coronary intervention: choosing statistical models, outcomes, time periods, and patient populations (Hannan and Wu). 2003;145:571-4 (Editorial)

Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? (Austin et al). 2003;145:27-35

Hierarchical modeling: its time has come (DeLong). 2003;145:16-18 (Editorial)

Limitations of current risk-adjustment models in the era of coronary stenting (Kizer et al). 2003;145:683-92

Monocyte chemoattractant protein-1

Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease (Matsui et al). 2003;145:330-3

Mortality

Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention (Gruberg et al). 2003;145:529-34

Long-term survival after resuscitation from cardiac arrest: cause for optimism and continued efforts (Rea and Eisenberg). 2003;145:749-50 (Editorial)

Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial (Al-Khatib et al). 2003;145:515-21

Time trends in long-term mortality after out-of-hospital cardiac arrest, 1980 to 1998, and predictors for death (Engdahl et al). 2003;145:826-33

Two-decade-long trends (1975-1997) in the incidence, hospitalization, and long-term death rates associated with complete heart block complicating acute myocardial infarction: a community-wide perspective (Spencer et al). 2003;145:500-7

Myocardial infarction

Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension (Brassard et al). 2003;145:e25

Association of the *Scal* atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease (Gruchaa et al). 2003;145:125-31

Atheromatous showers, periprocedural myocardial infarction, and fatality (Yen and Topol). 2003;145:933-5 (Editorial)

Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada (Batchelor et al). 2003;145:349-55

High levels of circulating endothelial microparticles in patients with acute coronary syndromes (Bernal-Mizrachi et al). 2003;145:962-70 (Progress cardiol.)

Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction (French et al). 2003;145:118-24

Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era (Ghazzal et al). 2003;145:1006-12

Myocardial infarction, diagnosis

Comparison of the predischARGE exercise thallium-201 perfusion defect after myocardial infarction with myocardium at risk measured during acute infarction with technetium-99m sestamibi imaging (Lapeyre et al). 2003;145:357-63

Effect of infarcted myocardium on diagnostic accuracy of exercise echocardiography for detecting noninfarct-related coronary artery lesions (Nishioka et al). 2003;145:162-8

Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction (Lapeyre et al). 2003;145:1051-7

Myocardial infarction, drug therapy

A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction (French et al). 2003;145:508-14

Assessing the success of fibrinolysis: can we let the interventionist rest? (Morrow and de Lemos). 2003;145:380-2 (Editorial)

Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction (Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)

Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry (Bahit et al). 2003;145:109-17

Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study (Borghi and Ambrosioni). 2003;145:80-7

Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence (Simpson et al). 2003;145:438-44

Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) Platelet substudy (Serebruany et al). 2003;145:636-42

Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction (Maia et al). 2003;145:e27

Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase (Wong et al). 2003;145:95-102

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? (Gerschütz and Bhatt). 2003;145:595-601 (Progress cardiol.)

Myocardial infarction, prognosis

C-Reactive protein in acute myocardial infarction: association with heart failure (Berton et al). 2003;145:1094-101

Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? (Austin et al). 2003;145:27-35

Ergometric score systems after myocardial infarction: prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction (Villella et al). 2003;145:475-83

Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials (Hasdai et al). 2003;145:73-9

Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community (Hellermann et al). 2003;145:742-8

Heart failure with preserved systolic function after myocardial infarction: a growing burden? (Ghali). 2003;145:575-8 (Editorial)

Hierarchical modeling: its time has come (DeLong). 2003;145:16-18 (Editorial)

History of depression, angina, and quality of life after acute coronary syndromes (Rumsfeld et al). 2003;145:493-9

Prognostic importance of systolic and diastolic function after acute myocardial infarction (Moller et al). 2003;145:147-53

Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial (Al-Khatib et al). 2003;145:515-21

Two-decade-long trends (1975-1997) in the incidence, hospitalization, and long-term death rates associated with complete heart block complicating acute myocardial infarction: a community-wide perspective (Spencer et al). 2003;145:500-7

Myocardial infarction, therapy

Double negatives (Kandzari and Tchong). 2003;145:9-12 (Editorial)

Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention (Brodie et al). 2003;145:708-15

No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention (Resnic et al). 2003;145:42-6

Outcomes of primary coronary angioplasty and angioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction (Poloski et al). 2003;145:855-61

Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America (Welsh et al). 2003;145:1-8 (Progress cardiol.)

Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction (Goldenberg et al). 2003;145:862-7

Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials (PCAT Collaborators). 2003;145:47-57

Temporal repolarization inhomogeneity and reperfusion arrhythmias in patients undergoing successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: impact of admission troponin T (Bonnemeier et al). 2003;145:484-92

Myocardial ischemia

Effect of dietary intervention and lipid-lowering treatment on brachial vasoreactivity in patients with ischemic heart disease and hypercholesterolemia (Sondergaard et al). 2003;145:e24

Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study (Jorgensen and Thaulow). 2003;145:1030-5

High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease (Jeppesen et al). 2003;145:103-8

To the Editor (Pugh et al). 2003;145:e11 (Letter)

Myocardial reperfusion

A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction (French et al). 2003;145:508-14

Assessing the success of fibrinolysis: can we let the interven-

tionist rest? (Morrow and de Lemos). 2003;145:380-2 (Editorial)

Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention (Brodie et al). 2003;145:708-15

Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America (Welsh et al). 2003;145:1-8 (Progress cardiol.)

Myocardial revascularization

Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program (Maynard et al). 2003;145:658-64

Assessing quality and outcomes for percutaneous coronary intervention: choosing statistical models, outcomes, time periods, and patient populations (Hannan and Wu). 2003;145:571-4 (Editorial)

Atheromatous showers, periprocedural myocardial infarction, and fatality (Yen and Topol). 2003;145:933-5 (Editorial)

β -Blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization (Jackson et al). 2003;145:875-81

Diabetes and percutaneous coronary intervention: the sweet smell of success? (Quinn and Moliterno). 2003;145:203-5 (Editorial)

Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years (Marso et al). 2003;145:270-7

Double negatives (Kandzari and Tchong). 2003;145:9-12 (Editorial)

Effect of cardiac rehabilitation on functional outcomes after coronary revascularization (Pasquali et al). 2003;145:445-51

No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention (Resnic et al). 2003;145:42-6

Predicting vascular complications in percutaneous coronary interventions (Piper et al). 2003;145:1022-9

Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era (Ghazzal et al). 2003;145:1006-12

Smoking and health outcomes after percutaneous coronary intervention (Haddock et al). 2003;145:652-7

Troponin I elevation and cardiac events after percutaneous coronary intervention (Ricciardi et al). 2003;145:522-8

Myocardial stunning

Atrial stunning: determinants and cellular mechanisms (Khan). 2003;145:787-94 (Progress cardiol.)

N

Natriuretic peptide, brain

B-Type natriuretic peptide: from bench to bedside (Adams et al). 2003;145:S34-46

Nesiritide

B-Type natriuretic peptide: from bench to bedside (Adams et al). 2003;145:S34-46

Rationale and design of the Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure (PRESERVED-HF) (Gheorghade et al). 2003;145:S55-7

Nickel

Nickel release after implantation of the Amplatzer occluder (Ries et al). 2003;145:737-41

No-reflow phenomenon

Double negatives (Kandzari and Tchong). 2003;145:9-12 (Editorial)

No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention (Resnic et al). 2003;145:42-6

O

Outcome assessment (health care)

- Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program (Maynard et al). 2003;145:658-64
- Assessing quality and outcomes for percutaneous coronary intervention: choosing statistical models, outcomes, time periods, and patient populations (Hannan and Wu). 2003;145:571-4 (Editorial)
- Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience (Reynolds et al). 2003;145:334-42
- Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? (Austin et al). 2003;145:27-35
- Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry (Bahit et al). 2003;145:109-17
- Hierarchical modeling: its time has come (DeLong). 2003;145:16-18 (Editorial)
- Surrogate end points in heart failure trials (Gheorghiade et al). 2003;145:567-70

P

Pacemaker, artificial

- Comparison of acute changes in left ventricular volume, systolic and diastolic functions, and intraventricular synchronicity after biventricular and right ventricular pacing for heart failure (Yu et al). 2003;145:e23
- Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing (Newman et al). 2003;145:430-7

Patent foramen ovale; see Heart septal defects, atrial

Patient compliance

- Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence (Simpson et al). 2003;145:438-44

Pediatric patient; see Child; Infant

Percutaneous coronary intervention; see Angioplasty; Myocardial revascularization; Stents

Peripheral vascular diseases

- Intravenous prostaglandin E₁ reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease (Matsui et al). 2003;145:330-3
- Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study (Cotter et al). 2003;145:622-7
- Prostaglandin E₁ temporarily decreases adhesion molecules (Palumbo et al) (Letter); (Gianetti and De Caterina) (Reply). 2003;145:e12, e13
- Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial (Rajagopalan et al). 2003;145:1114-18

Platelet aggregation inhibitors

- Angioplasty, inflammation, and antiplatelet agents (Molitero and Penn). 2003;145:563-6 (Editorial)
- Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry (Bauriedel et al). 2003;145:343-8
- Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism (Bonz et al). 2003;145:693-9

Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial (Gurbel et al). 2003;145:239-47

Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? (Malinin et al). 2003;145:397-403 (Curriculum cardi.)

Preventing stroke in patients with atrial fibrillation: current treatments and new concepts (Connolly). 2003;145:418-23 (Progress cardi.)

Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention (Furman et al). 2003;145:e6

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? (Gerschlager and Bhatt). 2003;145:595-601 (Progress cardi.)

What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? (Steinhuyl and Berger). 2003;145:971-8 (Progress cardi.)

Postoperative complications

Predicting vascular complications in percutaneous coronary interventions (Piper et al). 2003;145:1022-9

Practice guidelines

Adherence to practice guidelines: the role of specialty society guidelines (Leape et al). 2003;145:19-26

Physician adherence to clinical practice guidelines: does it really matter? (Brindis and Sennett). 2003;145:13-15 (Editorial)

Pravastatin

Effect of atorvastatin and pravastatin on serum C-reactive protein (Kent et al). 2003;145:e8

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study (Hague et al). 2003;145:643-51

Primary health care

Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care (Ahmed et al). 2003;145:1086-93

Cardiac management by pediatricians versus pediatric cardiologists in an inpatient academic center (Benun et al). 2003;145:424-9

Feedback intervention to reduce routine electrocardiogram use in primary care (Stafford). 2003;145:979-85

Impacting the use of the screening electrocardiogram (Cuffe). 2003;145:936-7 (Editorial)

Is specialty care associated with improved survival of patients with congestive heart failure? (Indridason et al). 2003;145:300-9

Specialty care for heart failure: does it improve outcomes? (Massie and Ansari). 2003;145:209-13 (Editorial)

Prostaglandins E

Intravenous prostaglandin E₁ reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease (Matsui et al). 2003;145:330-3

Prostaglandin E₁ temporarily decreases adhesion molecules (Palumbo et al) (Letter); (Gianetti and De Caterina) (Reply). 2003;145:e12, e13

PTCA; see Angioplasty, transluminal, percutaneous coronary

Pulmonary embolism

Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism (Mehta et al). 2003;145:821-5

Diagnosing and managing acute pulmonary embolism: role of cardiac troponins (Tapson). 2003;145:751-3 (Editorial)

Pulmonary hypertension; see Hypertension, pulmonary

Q

Quality of health care

- Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program (Maynard et al). 2003;145:658-64
- Assessing quality and outcomes for percutaneous coronary intervention: choosing statistical models, outcomes, time periods, and patient populations (Hannan and Wu). 2003;145:571-4 (Editorial)
- Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care (Ahmed et al). 2003;145:1086-93

Quality of life

- Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life (Newman et al). 2003;145:841-6
- Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing (Newman et al). 2003;145:430-7
- History of depression, angina, and quality of life after acute coronary syndromes (Rumsfeld et al). 2003;145:493-9
- Quality of life and time trade-off utility measures in patients with coronary artery disease (Melsop et al). 2003;145:36-41

R

Racial stocks

- Coronary artery calcification in black women and white women (Khurana et al). 2003;145:724-9
- Coronary calcium: is racial profiling necessary? (Redberg). 2003;145:579-81 (Editorial)
- Postexercise hypotension differs between white and black women (Pescatello et al). 2003;145:364-70
- The finer points of race and hypertension (Frazier and Alexander). 2003;145:206-8 (Editorial)

Radionuclide imaging

- Comparison of the predischARGE exercise thallium-201 perfusion defect after myocardial infarction with myocardium at risk measured during acute infarction with technetium-99m sestamibi imaging (Lapeyre et al). 2003;145:357-63
- Efficacy and time-efficiency of a "sonographer-driven" contrast echocardiography protocol in a high-volume echocardiography laboratory (Castello et al). 2003;145:535-41
- Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction (Lapeyre et al). 2003;145:1051-7
- Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? (Bourque et al). 2003;145:758-67 (Curriculum cardiol.)

Rehabilitation

- Effect of cardiac rehabilitation on functional outcomes after coronary revascularization (Pasquali et al). 2003;145:445-51

Renal failure; see Kidney failure**Reperfusion; see Myocardial reperfusion****Restenosis, coronary; see Coronary restenosis****Revascularization; see Myocardial revascularization****Risk assessment**

- Limitations of current risk-adjustment models in the era of coronary stenting (Kizer et al). 2003;145:683-92
- The problem of decompensated heart failure: nomenclature, classification, and risk stratification (Felker et al). 2003;145:S18-25

S

Saline solution, hypertonic

- Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects (Licata et al). 2003;145:459-66
- Hypertonic saline: a novel therapy for advanced heart failure? (Drazner and Palmer). 2003;145:377-9 (Editorial)

Sarpogrelate

- Sarpogrelate treatment reduces restenosis after coronary stenting (Fujita et al). 2003;145:e16

Seroepidemiologic studies

- Meta-analysis of sero-epidemiologic studies of the relation between *Chlamydia pneumoniae* and atherosclerosis: does study design influence results? (Bloemenkamp et al). 2003;145:409-17 (Progress cardiol.)

Sex factors

- Differential effects of exercise training in men and women with chronic heart failure (Keteyian et al). 2003;145:912-18
- Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex (Wong et al). 2003;145:888-95

Shock, cardiogenic

- Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention (Brodie et al). 2003;145:708-15

Silicon carbide

- Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome (Unverdorben et al). 2003;145:e17

Smoking

- Smoking and health outcomes after percutaneous coronary intervention (Haddock et al). 2003;145:652-7

Soybean proteins

- Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia (Blum et al). 2003;145:e7

Specialties, medical

- Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care (Ahmed et al). 2003;145:1086-93
- Cardiac management by pediatricians versus pediatric cardiologists in an inpatient academic center (Benun et al). 2003;145:424-9
- Is specialty care associated with improved survival of patients with congestive heart failure? (Indridason et al). 2003;145:300-9
- Specialty care for heart failure: does it improve outcomes? (Massie and Ansari). 2003;145:209-13 (Editorial)

SPECT; see Tomography, emission-computed, single-photon**Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors****Statistical models; see Models, statistical****Stenosis, coronary; see Coronary stenosis****Stents**

- Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry (Kandzari et al). 2003;145:868-74
- Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience (Reynolds et al). 2003;145:334-42
- Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome (Unverdorben et al). 2003;145:e17
- Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease (Almagor et al). 2003;145:248-53

- Limitations of current risk-adjustment models in the era of coronary stenting (Kizer et al). 2003;145:683-92
- Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT)—a randomized trial comparing a first-generation stent with a second-generation stent (Jørgensen et al). 2003;145:e5
- Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial (Gurbel et al). 2003;145:239-47
- Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus (Mazzeika et al). 2003;145:1013-21
- Predictors and implications of residual plaque burden after coronary stenting: an intravascular ultrasound study (Alfonso et al). 2003;145:254-61
- Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction (Goldenberg et al). 2003;145:862-7
- Randomized comparison of mounted versus unmounted stents: the multicenter COMUS trial (Schneider et al). 2003;145:e4
- Sarpogrelate treatment reduces restenosis after coronary stenting (Fujita et al). 2003;145:e16
- What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? (Steinhilber and Berger). 2003;145:971-8 (Progress cardiol.)
- Streptokinase**
- Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase (Wong et al). 2003;145:95-102
- Stress test; see Exercise test**
- Stroke; see Cerebrovascular accident**
- Sympathetic nervous system**
- Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation (Mehta et al). 2003;145:1078-85
- Syncope, vasovagal**
- Insulin sensitivity in young women with vasovagal syncope (Ruiz et al). 2003;145:834-40

T

- Tenecteplase**
- Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction (Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)
- Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) Platelet substudy (Serebruany et al). 2003;145:636-42
- Testosterone**
- To the Editor (Pugh et al). 2003;145:e11 (Letter)
- Tezosentan**
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4) (O'Connor et al). 2003;145:S58-9
- Thrombolytic therapy**
- A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction (French et al). 2003;145:508-14
- Assessing the success of fibrinolysis: can we let the interventionalist rest? (Morrow and de Lemos). 2003;145:380-2 (Editorial)
- Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase dur-

- ing treatment of acute myocardial infarction (Al-Shwafi et al). 2003;145:217-25 (Progress cardiol.)
- Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) Platelet substudy (Serebruany et al). 2003;145:636-42
- Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials (Hasdai et al). 2003;145:73-9
- Outcomes of primary coronary angioplasty and angioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction (Poloski et al). 2003;145:855-61
- Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction (Goldenberg et al). 2003;145:862-7
- Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials (PCAT Collaborators). 2003;145:47-57

Thrombophilia

- Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction (French et al). 2003;145:118-24

Thrombosis; see Embolism and thrombosis

Time factors

- Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention (Brodie et al). 2003;145:708-15
- Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America (Welsh et al). 2003;145:1-8 (Progress cardiol.)
- Quality of life and time trade-off utility measures in patients with coronary artery disease (Melsop et al). 2003;145:36-41

Tolvaptan

- Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure (Gheorghade et al). 2003;145:S51-4

Tomography, emission-computed, single-photon

- Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris (Patel and Iskandrian). 2003;145:952-61 (Curriculum cardiol.)

Tranilast

- Tranilast for restenosis: efficacious or not? (Morioka) (Letter); (Tamai) (Reply); (Holmes and Danoff) (Reply). 2003;145:e20, e21, e22

Transient ischemic attack; see Cerebrovascular accident

Treadmill test; see Exercise test

Tricuspid valve diseases; see Heart valve diseases

Triglycerides

- High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease (Jeppesen et al). 2003;145:103-8

Troponin

- Biochemical and clinical predictors of long-term outcome in patients with nonspecific chest pain and nondiagnostic electrocardiograms (Hillis et al). 2003;145:88-94
- Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism (Mehta et al). 2003;145:821-5
- Diagnosing and managing acute pulmonary embolism: role of cardiac troponins (Tapson). 2003;145:751-3 (Editorial)
- Measurements of serum cardiac troponin T in patients with heart failure (Sato et al) (Letter); (Perna et al) (Reply). 2003;145:e18, e19
- Temporal repolarization inhomogeneity and reperfusion ar-

rhythmias in patients undergoing successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: impact of admission troponin T (Bonnemeier et al). 2003;145:484-92

Troponin I elevation and cardiac events after percutaneous coronary intervention (Ricciardi et al). 2003;145:522-8

U

Ultrasonography

Automated three-dimensional assessment of coronary artery anatomy with intravascular ultrasound scanning (Klingensmith et al). 2003;145:795-805 (Progress cardiol.)

Detection of endothelial dysfunction with brachial artery ultrasound scanning (Faulx et al). 2003;145:943-51 (Curriculum cardiol.)

Predictors and implications of residual plaque burden after coronary stenting: an intravascular ultrasound study (Alfonso et al). 2003;145:254-61

V

Valsartan

What did we learn from the OPTIMAAL trial? What can we expect from VALLANT? (Dickstein). 2003;145:754-7 (Editorial)

Vasodilator agents

Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension (Gavazzi et al). 2003;145:310-16

Ventricular arrhythmias; see Arrhythmia

Ventricular dysfunction, left

Diastolic dysfunction after coronary artery bypass grafting: a frequent finding of clinical significance not influenced by intravenous calcium (Ekery et al). 2003;145:896-902

Prognostic value of QT interval and QT dispersion in patients with left ventricular systolic dysfunction: results from a cohort of 2265 patients with an ejection fraction of $\leq 40\%$ (Padmanabhan et al). 2003;145:132-8

Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction (Fingberg et al). 2003;145:e1

Ventricular function, left

β -Blockers and reverse remodeling: what are the implications? (Francis and Tang). 2003;145:200-2 (Editorial)

Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age (Feinberg et al). 2003;145:549-53

Comparison of acute changes in left ventricular volume, systolic and diastolic functions, and intraventricular synchronicity after biventricular and right ventricular pacing for heart failure (Yu et al). 2003;145:e23

Efficacy and time-efficiency of a "sonographer-driven" contrast echocardiography protocol in a high-volume echocardiography laboratory (Castello et al). 2003;145:535-41

Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community (Hellermann et al). 2003;145:742-8

Heart failure with preserved systolic function after myocardial infarction: a growing burden? (Ghali). 2003;145:575-8 (Editorial)

Marked improvement in left ventricular ejection fraction during long-term β -blockade in patients with chronic heart failure: clinical correlates and prognostic significance (Metra et al). 2003;145:292-9

Prognostic importance of systolic and diastolic function after acute myocardial infarction (Møller et al). 2003;145:147-53

Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction (Lapeyre et al). 2003;145:1051-7

Ventricular function, right

Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension (Gavazzi et al). 2003;145:310-16

Vitamin C; see Ascorbic acid

W

Warfarin

Preventing stroke in patients with atrial fibrillation: current treatments and new concepts (Connolly). 2003;145:418-23 (Progress cardiol.)

Women; see also Sex factors

Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis (Sullivan). 2003;145:190-4 (Editorial)

Coronary artery calcification in black women and white women (Khurana et al). 2003;145:724-9

Coronary calcium: is racial profiling necessary? (Redberg). 2003;145:579-81 (Editorial)

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study (Hague et al). 2003;145:643-51

Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia (Blum et al). 2003;145:e7

Endothelium-independent coronary microvascular function: all vessels are not created equally (Hasdai). 2003;145:567-8 (Editorial)

Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease: implications for clinical practice (Marroquin et al). 2003;145:628-35

Insulin sensitivity in young women with vasovagal syncope (Ruiz et al). 2003;145:834-40

Postexercise hypotension differs between white and black women (Pescatello et al). 2003;145:364-70

The finer points of race and hypertension (Frazier and Alexander). 2003;145:206-8 (Editorial)

Z

Zofenopril

Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study (Borghi and Ambrosioni). 2003;145:80-7

